idarubicin has been researched along with Acute Myelogenous Leukemia in 542 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (3.51) | 18.7374 |
| 1990's | 92 (16.97) | 18.2507 |
| 2000's | 141 (26.01) | 29.6817 |
| 2010's | 233 (42.99) | 24.3611 |
| 2020's | 57 (10.52) | 2.80 |
| Authors | Studies |
|---|---|
| Anuchapreeda, S; Berkland, C; Chiampanichayakul, S; Chueahongthong, F; Tima, S | 1 |
| Chen, Q; Chen, Y; Hu, J; Li, J; Li, X; Mao, Y; Shen, Y; Sheng, Y; Wang, L; Weng, X; Wu, J; Wu, M; You, J; Zhang, Y; Zhao, H; Zheng, Y | 1 |
| Kuo, DJ; Le Floch, N; Spies, JM; Wong, V | 1 |
| Michaelis, LC | 1 |
| Burnett, A; Dennis, M; Hills, R; Kjeldsen, L; Russell, N | 1 |
| Chen, C; Fu, H; Jin, C; Ke, B; Kong, C; Li, A; Liu, T; Zhang, Y; Zhang, Z; Zhu, Q | 1 |
| Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF | 1 |
| Adès, L; Amé, S; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Braun, T; Chermat, F; Chevret, S; Cheze, S; Cluzeau, T; de Botton, S; Dimicoli-Salazar, S; Duployez, N; Fenaux, P; Guerci-Bresler, A; Laribi, K; Marolleau, JP; Nimubona, S; Park, S; Peterlin, P; Preudhomme, C; Quesnel, B; Recher, C; Stamatoullas, A; Thepot, S; Toma, A; Vey, N; Wattel, E; Wickenhauser, S; Zerazhi, H | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Bravo, GM; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, SA; Xiao, L; Yilmaz, M | 1 |
| Elonen, E; Huhtala, H; Itälä-Remes, M; Jantunen, E; Kairisto, V; Kauppila, M; Koistinen, P; Koivunen, E; Kolonen, A; Kuittinen, T; Nousiainen, T; Ollikainen, H; Pelliniemi, TT; Penttilä, K; Porkka, K; Pyörälä, M; Räty, R; Rauhala, A; Rimpiläinen, J; Rintala, H; Ruutu, T; Säily, M; Sankelo, M; Silvennoinen, R; Sinisalo, M; Volin, L | 1 |
| Jiang, Y; Ye, Z | 1 |
| Al-Kali, A; Alkhateeb, H; Begna, KH; Chen, D; Elliott, MA; Gangat, N; Hogan, WJ; Hook, CC; Ketterling, RP; Litzow, MR; Mangaonkar, A; Pardanani, A; Patnaik, MS; Shah, M; Tefferi, A; Viswanatha, D | 1 |
| Agrawal, N; Ahmed, R; Bansal, N; Bhurani, D; Halder, R; Mehta, P; Rainchwar, S; Singh, R; Verma, M | 1 |
| Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X | 1 |
| Fan, Z; Huang, F; Li, X; Lin, D; Lin, R; Liu, H; Liu, Q; Liu, X; Shi, P; Sun, J; Sun, Z; Wang, Z; Wu, M; Xiong, Y; Xu, J; Xu, N; Xuan, L; Zhang, Y | 1 |
| Chang, YJ; Gong, LZ; Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Liu, XH; Qin, YZ; Ruan, GR; Tang, FF; Wang, J; Wang, Y; Yu, WJ; Zhao, XS; Zhu, XL | 1 |
| Albano, F; Attolico, I; Carluccio, P; Contento, C; Delia, M; Di Gennaro, D; Gagliardi, VP; Musto, P | 1 |
| Bhojwani, D; Dao, J; Doan, A; Freyer, DR; Gaynon, P; Hadar, AJ; Huang, HKT; Kovach, AE; Malvar, J; Orgel, E; Parekh, C; Posch, LC; Raca, G; Rushing, T; Stokke, J | 1 |
| Bocchia, M; Malchiodi, M; Santoni, A; Sicuranza, A; Zappone, E | 1 |
| Feng, B; Fu, JF; Kan, WJ; Li, J; Li, JN; Liu, MM; Luo, GH; Song, N; Tu, YT; Wang, HL; Wei, G; Wu, WB; Xu, GY; Xu, R; Zhou, YB | 1 |
| Cenin, DA; Donald Harvey Iii, R; Kovacsovics, T; Kurish, HP; Lee, JS; Li, BKT; Lo, M; Patel, S; Prelewicz, S; Schlafer, D; Wagner, CB; Walchack, R; Wasef, B; Ying, J | 1 |
| Cao, J; Chen, Y; Dong, QF; Hu, JD; Li, F; Luo, LT; Sang, YQ; Wang, J; Wang, SL; Yang, T; Ye, YZ; Zhang, L; Zheng, J; Zheng, XY | 1 |
| Altman, JK; Asch, A; Cherry, M; Cooper, BW; Cruz, JC; Gill, SC; Hasabou, N; Hill, JE; James, AJ; Jurcic, JG; Levis, MJ; Lin, TL; Perl, AE; Podoltsev, NA; Pratz, KW; Rich, ES; Schiller, GJ; Wu, R | 1 |
| Bengoudifa, BR; Caillot, D; Cluzeau, T; Farkas, F; Gilotti, G; Griskevicius, L; Hodzic, S; Legrand, O; Luppi, M; Minotti, C; Montesinos, P; Rambaldi, A; Sierra, J; Thomas, X; Venditti, A | 1 |
| Fredman, D; Gafter-Gvili, A; Raanani, P; Sherban, A; Shimony, S; Stahl, M; Wolach, O; Yeshurun, M | 1 |
| Bataller, A; Borthakur, G; Bose, P; Champlin, R; Daver, N; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Islam, R; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Marx, KR; Molica, M; Pemmaraju, N; Rausch, CR; Ravandi, F; Shpall, E; Tidwell, RS; Wang, S; Ylimaz, M | 1 |
| Abe, Y; Ishida, T; Kasai, Y; Kasuya, Y; Kikuchi, T; Nomura, M; Norihama, Y; Oda, Y; Ogura, M; Sato, K; Takei, T; Tsukada, N | 1 |
| Adès, L; Fenaux, P; Sébert, M | 1 |
| Chung, W; Cui, J; Han, J; Heo, JY; Jang, Y; Ju, X; Kim, SJ; Kweon, GR; Lee, MJ; Lee, YL; Ryu, MJ; Son, JH; Song, IC | 1 |
| Alonso Domínguez, JM; Arquero, T; Atance, M; Chamizo, C; Piris, MA; Prieto-Torres, L; Requena, L; Rodriguez-Pinilla, SM; Salgado, RN; Soto, C | 1 |
| Aragüés, M; Chicharro, P; Fraga, J; Llamas-Velasco, M; Reolid, A; Rodríguez-Jiménez, P | 1 |
| Bian, Y; Huang, C; Ma, S; Ma, W; Miao, L; Miao, M; Xia, F; Yu, D | 1 |
| Abu Samra, M; Basara, N; Benner, A; Bentz, M; Döhner, H; Döhner, K; Fiedler, W; Gaidzik, VI; Ganser, A; Girschikofsky, M; Götze, K; Greil, R; Hertenstein, B; Heuser, M; Horst, HA; Kapp-Schwoerer, S; Kindler, T; Koller, E; Krauter, J; Krzykalla, J; Leis, C; Lübbert, M; Martens, U; Mayer, K; Nachbaur, D; Paschka, P; Schleicher, J; Schlenk, RF; Schroeder, T; Thol, F; Wattad, M; Weber, D; Wulf, G | 1 |
| Bang, SM; Byun, JM; Hong, J; Kim, I; Koh, Y; Lee, J; Lee, JO; Shin, DY; Suh, KJ; Yoon, SS | 1 |
| Brossart, P; Glasmacher, A; Hahn-Ast, C; Mayer, K; Schmidt-Wolf, IGH; Schwab, K; von Lilienfeld-Toal, M | 1 |
| Gong, L; Huang, X; Jia, J; Jiang, H; Jiang, Q; Lai, Y; Liu, K; Liu, X; Lu, R; Lu, S; Ruan, G; Shi, H; Wang, J; Wang, Y; Wu, Y; Xu, L; Yan, C; Zhang, X; Zhao, X | 1 |
| Bashey, A; Holland, HK; Morris, LE; Solh, MM; Solomon, SR; Zhang, X | 1 |
| Bohannon, L; Brander, D; Chan, C; Chao, N; de Castro, C; Diehl, L; Dillon, LW; Erba, H; Gadi, VK; Galal, A; Hourigan, CS; Jauhari, S; LeBlanc, T; Li, Z; Lyu, J; Meyer, E; Nixon, AB; Rao, AV; Rizzieri, DA; Shelby, R; Siamakpour-Reihani, S; Staats, J; Stefanovic, A; Sung, AD; Wong, HY; Xie, J | 1 |
| Aplenc, R | 1 |
| Capelli, D; Chiarucci, M; Discepoli, G; Fiorentini, A; Leoni, P; Menotti, D; Olivieri, A; Poloni, A; Saraceni, F | 1 |
| Shi, T; Xie, W; Yang, X; Ye, X; Zhao, S; Zhu, J; Zhu, L | 1 |
| Kanaya, M; Kondo, T | 1 |
| Amberg, S; Bokemeyer, C; Christine Wilke, A; Chromik, J; Deppermann, U; Fiedler, W; Ganser, A; Heuser, M; Janning, M; Kebenko, M; Kranich, AL; Modemann, F; Schlipfenbacher, V; Serve, H; Theile, S; Thol, F | 1 |
| Deeren, D | 1 |
| Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X | 1 |
| Cheong, JW; Chung, H; Hyun, SY; Jang, JE; Kim, JS; Kim, SJ; Kong, JH; Lee, JI; Min, YH; Na, EJ; Shim, KY | 1 |
| Oniashvilli, N; Pasvolsky, O; Raanani, P; Rozovski, U; Rubinstein, M; Sela-Navon, M; Shargian-Alon, L; Wolach, O; Yahav, D; Yeshurun, M | 1 |
| Bankar, A; Bolster, L; Brandwein, JM; Hallett, D; Hamilton, M; Karkhaneh, M; Liew, E; Patterson, J; Saini, L; Taparia, M; Van Slyke, T; Wu, C; Zhu, N | 1 |
| Au, CH; Chan, TL; Cheng, GH; Cheng, KC; Cheung, AK; Ip, HW; Javed, A; Kho, B; Kwong, YL; Lam, SS; Lau, CK; Lau, JS; Lee, HK; Leung, AY; Leung, SY; Lin, CH; Lin, SY; Luk, TH; Ma, ES; Man, CH; Ng, MH; Ng, NK; Saw, NY; Sim, JP; Siu, LP; So, JC; Tang, WF; Tsui, SP; Wong, KF; Yip, SF; Zhang, C | 1 |
| Deng, M; Feng, J; Jiang, Y; Jiang, Z; Li, P; Liao, N; Shi, P; Song, H; Xu, B; Zha, J; Zhao, H | 1 |
| Azar, MM; Pischel, L; Ringer, M | 1 |
| Anderson, LD; Awan, F; Bergstrom, CP; Chen, W; Chung, S; Collins, R; Dahiya, S; Kansagra, A; Madanat, Y; Patel, P; Ramakrishnan, P; Rizvi, S; Vusirkala, M; Yan, J; Zhang, CC; Zhu, H | 1 |
| Ashihara, E; Hattori, Y; Hosogi, S; Takata, K; Toda, Y; Wakabayashi, R | 1 |
| Chen, XJ; Chen, YM; Guo, Y; Liu, F; Liu, LP; Liu, TF; Liu, XM; Quan Qi, B; Ruan, M; Yang, WY; Zhang, AL; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Benitez, LL; Bixby, DL; Boyer, D; Burke, PW; Lee, W; Marini, BL; Perissinotti, AJ; Pettit, K; Reid, JH | 1 |
| Abedi, M; Hoeg, RT; Jonas, BA; Krishnan, R; Moskoff, BN; Rosenberg, AS; Tenold, ME; Tuscano, JM | 1 |
| Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M | 1 |
| Davainis, L; Griskevicius, L; Maneikis, K; Peceliunas, V; Pileckyte, R; Staras, V; Trociukas, I; Vaitekenaite, V; Zucenka, A; Zvirblis, T | 1 |
| Wang, D; Wang, ZD; Zhang, CH; Zhang, Q | 1 |
| Ang, AL; Ho, LP; Ng, HJ; Ong, SY; Yeo, PM | 1 |
| Koyama, T; Shinki, H; Tsunaka, M | 1 |
| Balakrishnan, VS | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Bosi, A; Coltro, G; Guglielmelli, P; Mannelli, F; Pacilli, A; Vannucchi, AM | 1 |
| Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L | 2 |
| Blijlevens, NMA; Kox, M; Leijte, GP; Pickkers, PP; Scheffer, GJ; Timmermans, K | 1 |
| Blombery, P; Cummins, K; Ekert, PG; Glaser, SP; Guthridge, MA; Huang, DCS; Jabbour, A; Lackovic, K; Lessene, G; Moujalled, DM; Nguyen, NY; Pomilio, G; Rijal, S; Roberts, AW; Segal, D; Teh, TC; Thompson, E; Wei, AH | 1 |
| Chen, K; Deng, M; Deng, S; Li, J; Li, P; Li, Y; Wang, Y; Xu, B; Zhang, L; Zhou, Y | 1 |
| Gu, MJ; Kim, MJ; Kim, MK; Kim, YK | 1 |
| Cen, J; Chen, S; Pan, J; Shao, H; Wu, C; Yang, Q | 1 |
| Albano, F; Carluccio, P; Casieri, P; Delia, M; Mestice, A; Pasciolla, C; Pastore, D; Ricco, A; Rossi, AR; Specchia, G | 1 |
| Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M | 1 |
| Al Harthy, M; Gondek, LP; Murray, JC; Pallazola, VA; Webster, J; Zimmerman, SL | 1 |
| Evans, AG; Goorha, S; Hobbs, ALV; Leonard, JM; Mills, EL; Seligson, ND | 1 |
| Ballerini, F; Cagnetta, A; Carminati, E; Cea, M; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Matarese, S; Miglino, M; Minetto, P; Raiola, AM | 1 |
| Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
| Baccarani, M; Candoni, A; Fanin, R; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Martinelli, G; Papayannidis, C; Simeone, E; Visani, G | 1 |
| Advani, AS; Appelbaum, FR; Erba, HP; Li, H; Liedtke, M; List, AF; Medeiros, BC; Michaelis, LC; O'Dwyer, K; Othus, M | 1 |
| Aragon-Miguel, R; Burillo-Martinez, S; Calleja-Algarra, A; Ortiz-Romero, PL; Prieto-Barrios, M; Rodriguez-Peralto, JL; Tous-Romero, F; Velasco-Tamariz, V; Zarco-Olivo, C | 1 |
| Barghout, SH; Chan, SM; Claudio, J; Gronda, M; Gupta, V; Heath, E; Hurren, R; Kamel-Reid, S; Kavanagh, S; Khalaf, D; Liyanage, SU; Lutynski, A; Maze, D; Minden, MD; Rostom, A; Rydlewski, A; Schimmer, AD; Schuh, AC; Sibai, H; Siriwardena, TP; Stockley, TL; Sukhai, M; Yee, K; Zhang, T | 1 |
| Amrolia, P; Breslin, P; Cummins, M; De La Fuente, J; Gassas, A; Gibson, B; Hiwarkar, P; Hough, R; James, B; Lawson, S; Patrick, K; Petterson, T; Potter, M; Shenton, G; Sivaprakasam, P; Skinner, R; Slatter, M; Veys, P; Vora, A; Wynn, R | 1 |
| Braun, JT; Fesler, MJ; Freter, CE; Lionberger, JM; Petruska, PJ; Reddy, DV; Schoen, MW; Woelich, SK | 1 |
| Baer, MR; El Chaer, F; Law, JY; Mohindra, P; Singh, ZN; Zou, Y | 1 |
| Huang, WB; Li, MW; Lin, P; Wang, W; Yang, XN; Yao, HY | 1 |
| Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J | 1 |
| Peña, M; Ribera, JM; Serra, J | 1 |
| Arellano, M; Carlisle, JW | 1 |
| Ali, A; Burnett, AK; Cahalin, P; Freeman, S; Hills, RK; Hunter, A; Nielsen, OJ; Russell, NH; Thomas, IF | 1 |
| Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I | 1 |
| Haack, K; Henderson, PT; Jonas, BA; Malfatti, MA; Pan, CX; Scharadin, TM; Turteltaub, KW | 1 |
| Kungwankiattichai, S; Owattanapanich, N; Owattanapanich, W; Ruchutrakool, T; Ungprasert, P | 1 |
| Dührsen, U; Hanoun, M; Noppeney, R; Westhus, J | 1 |
| Gourd, E | 1 |
| Becker, H; Döhner, H; Döhner, K; Fiedler, W; Gaidzik, VI; Ganser, A; Götze, KS; Greil, C; Heuser, M; Janning, M; Kebenko, M; Könecke, C; Krauter, J; Lübbert, M; Neuhaus, B; Papkalla, A; Paschka, P; Reimer, P; Schlenk, RF; Thol, F; Verbeek, M; Wattad, M | 1 |
| Ballesteros, J; Bergua, J; Colorado, M; García-Boyero, R; Gil, C; Gorrochategui, J; Hernández-Campo, P; Herrera, P; Jiménez-Bravo, S; Lavilla, E; Linares Gómez, M; López, JA; Martínez-Cuadrón, D; Martínez-López, J; Montesinos, P; Moscardó, F; Pérez-Oteyza, J; Pérez-Simón, JA; Primo, D; Rodríguez, G; Rojas, JL; Sanz, M; Serrano, J; Tormo, M; Troconiz, I; Vidriales, MB; Villoria, J; Vives, S | 1 |
| Abdalla, K; Abrar, MB; AlAzmi, AA; Elimam, N; Jastaniah, W; Mustafa, O | 1 |
| Alfayez, M; Boddu, PC; Borthakur, G; Cortes, J; Daver, NG; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Konopleva, M; Naqvi, K; Pierce, S; Ravandi, F; Short, NJ; Yilmaz, M | 1 |
| Ashizawa, M; Fujiwara, SI; Hatano, K; Kako, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Kimura, SI; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Sato, K; Shirato, Y; Toda, Y; Yamamoto, C; Yamasaki, R | 1 |
| Baskhaeva, GA; Davidiva, JO; Drokov, MY; Dvirnik, VN; Fidarova, ZT; Galtseva, IV; Gavrilina, OA; Kokhno, AV; Kulikov, SM; Kuzmina, LA; Kuznetsova, SA; Lobaova, TI; Loukianova, IA; Obukhova, TN; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Sudarikov, AB; Troitskaya, VV; Vasilyeva, VA | 1 |
| Cook, JR; Nomani, L; Rogers, HJ | 1 |
| Benner, A; Bernhard, H; Derigs, HG; Döhner, H; Döhner, K; Gaidzik, V; Ganser, A; Girschikofsky, M; Göhring, G; Grießhammer, M; Haase, D; Herr, W; Hertenstein, B; Heuser, M; Koller, E; Krauter, J; Kremers, S; Kuendgen, A; Lange, E; Martens, UM; Paschka, P; Ringhoffer, M; Salih, HR; Schlenk, RF; Teleanu, V; Thol, F; Wattad, M; Weber, D; Westermann, J; Wolf, D; Wulf, G | 1 |
| Arnold, AJ; Gilmour, GS; Koch, MW | 1 |
| Devidas, M; Gaynon, PS; Ji, L; Sather, H; Seibel, NL; Steinherz, PG; Xu, X | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M; Woo, JM | 1 |
| Adige, S; Ambulos, NP; Baer, MR; Bentzen, SM; Carter-Cooper, BA; Duffy, A; Emadi, A; Lapidus, RG; Law, JY; Patzke, C; Zou, Y | 1 |
| Guo, X; Zhang, X | 2 |
| Ahmed, Z; Batanian, J; Davaro, E; Verma, N | 1 |
| Borthakur, G; Economides, MP; McCue, D; Pemmaraju, N | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Candoni, A; Cerrano, M; Crisà, E; D'Ardia, S; Dubbini, MV; Ferrero, D; Zannier, ME | 1 |
| Abou Dalle, I; Andreeff, M; Borthakur, G; Bose, P; Cortes, J; Daver, N; DiNardo, C; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Loghavi, S; Naqvi, K; Nogueras González, GM; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, NJ; Yalniz, F; Yilmaz, M | 1 |
| Bi, S; Chen, K; Chen, XL; Feng, L; Fu, G; Jiang, S; Lin, C; Xu, B; Yang, Q; Zhang, L; Zhao, H; Zhou, Y | 1 |
| Audisio, E; D'Ardia, S; Di Bello, C; Di Celle, PF; Frairia, C; Inghirami, G; Marmont, F; Messa, E; Pich, A; Riera, L; Sismondi, F; Toppino, D; Vitolo, U | 1 |
| Stone, RM | 1 |
| Chen, B; Ouyang, J; Wang, J; Xu, JY; Yang, YG; Zhang, QG; Zhou, M; Zhou, RF | 1 |
| Li, XY; Li, Y; Wang, X | 1 |
| Aquino, S; Avenoso, D; Ballerini, F; Bergamaschi, M; Clavio, M; Colombo, N; Cruciani, F; De Astis, E; Ghiggi, C; Gobbi, M; Grasso, R; Guolo, F; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G | 1 |
| Creutzig, U; Dworzak, MN; Reinhardt, D; Ritter, J; Schellong, G; Zimmermann, M | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, MN; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Ritter, J; Sander, A; Schrauder, A; Starý, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M | 1 |
| Falk, IJ; Fyrberg, A; Gréen, H; Hermanson, M; Höglund, M; Lotfi, K; Nahi, H; Palmqvist, L; Paul, E; Rosenquist, R; Stockelberg, D; Wei, Y | 1 |
| Andreeff, M; Borthakur, G; Brandt, M; Choi, S; Cortes, J; Daver, N; Du, M; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; Kornblau, S; Nazha, A; Pemmaraju, N; Ravandi, F | 1 |
| Dailey, ME; Gorgan, MA; Mar, N; Vredenburgh, JJ | 1 |
| Burnett, AK; Gibson, BE; Hills, RK; Hunter, AE; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Ichikawa, M; Kobayashi, T; Kurokawa, M; Nannya, Y | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Handa, H; Hatsumi, N; Jimbo, T; Miyawaki, S; Nojima, Y; Saitoh, T; Sakura, T; Shimizu, H; Takada, S | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Guzman, ML; Hayslip, J; Howard, DS; Jordan, CT; Liesveld, J; Phillips, GL; Weiss, H | 1 |
| Béné, MC; Bonmati, C; Bouscary, D; Cahn, JY; Delaunay, J; Dreyfus, F; Escoffre-Barbe, M; Fegueux, N; Guardiola, P; Guièze, R; Guyotat, D; Harousseau, JL; Hunault, M; Ifrah, N; Jourdan, E; Lioure, B; Lissandre, S; Luquet, I; Ojeda-Uribe, M; Pigneux, A; Randriamalala, E; Récher, C; Vey, N | 1 |
| Chang, CS; Hsiao, HH; Hsu, JF; Lin, SF; Liu, TC; Liu, YC; Lu, PL; Wu, CH | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Bergeland, T; Blau, IW; Gianella-Borradori, A; Gjertsen, BT; Huguet-Rigal, F; Jacobsen, TF; Johansen, M; Kindler, T; Krauter, J; Krug, U; Rizzieri, D; Schlenk, RF; Thomas, X; Vey, N | 1 |
| Chen, F; Guo, X; Liu, Y; Shi, P; Wang, S; Wang, W; Xu, B | 1 |
| Cui, J; Gao, S; Han, W; Li, W; Liu, X; Su, L; Tan, Y; Yu, P | 1 |
| Andreeff, M; Arana Yi, C; Borthakur, G; Brandt, M; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; Levis, M; Luthra, R; O'Brien, S; Pierce, S; Pratz, K; Ravandi, F; Thomas, D | 1 |
| Chung, NG; Jang, W; Kim, M; Lee, JW | 1 |
| Tohyama, K | 1 |
| Miyawaki, S | 1 |
| Jang, JH; Jung, CW; Jung, HA; Kim, K; Kim, SJ; Maeng, CH; Park, S | 1 |
| Bae, SH; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Park, JH; Ryoo, HM | 1 |
| Cabrera, JR; de Laiglesia, A; de Pablo, R; Dorado, N; Forés, R; García-Marco, JA; Lario, A; Piris, M; Regidor, C; Vilches, C | 1 |
| Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R | 1 |
| Appelbaum, FR; Becker, PS; Boehm, A; Dean, C; Deeg, HJ; Estey, EH; Hendrie, PC; Lionberger, JM; Mawad, R; Ostronoff, F; Pagel, JM; Sandhu, VK; Scott, BL; Shadman, M; Shannon-Dorcy, K; Walter, RB; Xie, H | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Hong, SK; Kim, EC; Sung, JY | 1 |
| Brossart, P; Brugger, W; Derigs, HG; Döhner, H; Döhner, K; Gaidzik, VI; Göttlicher, M; Götze, K; Greil, R; Heil, G; Held, G; Horst, HA; Kirchen, H; Köhne, CH; Koller, E; Kremers, S; Matzdorff, A; Nachbaur, D; Paschka, P; Raghavachar, A; Ringhoffer, M; Schlenk, RF; Tassara, M; Wattad, M; Wulf, G | 1 |
| Chen, LJ; Hong, M; Li, JY; Liu, P; Lu, H; Miao, KR; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R; Zhang, SJ | 1 |
| Desjonqueres, A; Eveillard, M | 1 |
| Adachi, S; Hamamoto, K; Hanada, R; Hayashi, Y; Horibe, K; Imaizumi, M; Kobayashi, R; Kudo, K; Miyamura, T; Morimoto, A; Moritake, H; Nakayama, H; Shimada, A; Tabuchi, K; Taga, T; Tawa, A; Tomizawa, D; Tsuchida, M; Tsukimoto, I; Yabe, H | 1 |
| Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
| Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO | 1 |
| Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Aldayel, AS; Konoplev, S; Medeiros, LJ; Rich, A; Sun, J; Yin, CC | 1 |
| Advani, AS; Appelbaum, FR; Copelan, E; List, AF; McDonough, S; Mulford, DA; Othus, M; Sekeres, MA; Willman, C | 1 |
| Bradstock, KF; Collins, M; Cull, G; Di Iulio, J; Enno, A; Hahn, U; Lewis, ID; Link, E; Marlton, P; Schwarer, A; Seymour, JF; Szer, J | 1 |
| Chen-Liang, TH; Florensa, L; Jerez, A; Ortuño, FJ | 1 |
| Chen, J; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Wei, J; Yu, W | 1 |
| Drokov, MIu; Galstian, GM; Kessel'man, SA; Kliasova, GA; Kulikov, SM; Kuz'mina, LA; Obukhova, TN; Paramonova, EV; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Troitskaia, VV; Vasil'eva, VA | 1 |
| Gan, SL; Liu, YF; Sun, H; Tian, DH; Xie, XS; Xing, HZ | 1 |
| Lima, KM; Morais, VD; Onsten, TG; Ribeiro, RA; Sekine, L; Ziegelmann, PK | 1 |
| Basso, G; Beqiri, V; Bisio, V; Buldini, B; Fagioli, F; Locatelli, F; Manara, E; Masetti, R; Pession, A; Pigazzi, M; Putti, MC; Rizzari, C; Rondelli, R; Tregnago, C | 1 |
| Ho, A; Lao, Z; Wong, GC; Yiu, R | 1 |
| Hebeda, KM; Janssen, NA; Stevens, WB; van der Velden, WJ | 1 |
| Grimwade, D; Kayser, S; Schlenk, RF; Walter, RB; Yosuico, VE | 1 |
| Becker, PS; Chen, TL; Dean, C; Estey, EH; Hendrie, PC; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Shadman, M; Shannon-Dorcy, K; Walter, RB | 1 |
| Brunet, S; Clapés, V; Guardia, R; Oriol, A; Piernas, S; Ribera, JM; Sierra, J; Subirà, M; Vives, S | 1 |
| Borthakur, G; Brandt, M; Cortes, J; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Wang, X | 1 |
| Bao, L; Huang, X; Jia, J; Jiang, B; Jiang, H; Jiang, Q; Lu, J; Wang, J; Yang, S; Zhang, Y; Zhao, T; Zhu, H | 2 |
| Menon, MP; Vidholia, A | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 1 |
| Bae, SH; Choi, Y; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Ryoo, HM | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, M; Fleischhack, G; Graf, N; Gruhn, B; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Stray, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M | 1 |
| Chen, J; Li, X; Tan, Y; Xu, S | 1 |
| Su, YZ; Sun, NT; Wang, CB; Zhou, Y | 1 |
| Brunet, S; Castro, N; Chillón, MC; Díez-Campelo, M; González, M; Herrera, P; López, J; Mateo, M; Mateos, MV; Montesinos, P; Ocio, EM; Olave, MT; Oriol, A; Pérez-Simón, JA; Prieto-Conde, MI; San Miguel, JF; Sanz, MÁ; Vidriales, MB | 1 |
| Anacak, Y; Aydinok, Y; Balkan, C; Delcastello, BE; Kamer, SA; Karadaş, N; Karapinar, DY; Kavakli, K | 1 |
| Baty, J; Chang, GS; Christopher, M; Demeter, RT; DiPersio, JF; Duncavage, EJ; Fronick, C; Fulton, R; Graubert, TA; Griffith, M; Griffith, OL; Heath, SE; Helton, NM; Hundal, J; Ketkar-Kulkarni, S; Klco, JM; Kulkarni, S; Lamprecht, TL; Larson, DE; Ley, TJ; Link, DC; Magrini, V; Mardis, ER; Miller, CA; O'Laughlin, M; Ozenberger, BA; Payton, JE; Petti, A; Radich, JP; Shen, D; Spencer, DH; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Blanco-Prieto, MJ; Castello-Cros, R; Cirauqui, C; Estella-Hermoso de Mendoza, A; Imbuluzqueta, E; Odero, MD; Pippa, R | 1 |
| Bezerra, MA; Bezerra, MF; de Assis, RA; de Mello, MR; Duarte, BK; Fernandes, E; Lima, AS; Lorand-Metze, I; Lucena-Araujo, AR; Machado, CG; Oliveira, MM; Pagnano, K; Ramos, CF; Souto, FR | 1 |
| Horinek, A; Korabecna, M; Koutova, L; Lysak, D; Pazourkova, E; Pospisilova, S; Sterbova, M; Svobodova, I | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Amadori, S; Baron, F; Bron, D; de Witte, T; Halkes, C; Meert, L; Muus, P; Selleslag, D; Suciu, S; Willemze, R | 1 |
| Ahn, MS; Choi, JH; Choi, YW; Jeong, SH; Kang, SY; Lee, HW; Park, JS | 1 |
| Chen, J; Liu, Y; Shen, Y; Wu, D | 1 |
| Jamy, O; Martin, MG; Wiedower, E | 1 |
| Gou, H; Hu, X; Lu, X; Peng, W; Shang, M; Song, X; Ye, Y; Ying, B; Zhang, J; Zhao, Z; Zhou, J; Zhou, Y | 1 |
| Kim, SY; Lee, MH | 1 |
| Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S | 1 |
| Fang, L; Hu, N; Lin, Y; Pan, L; Qin, T; Qu, S; Ru, K; Wang, J; Xiao, Z; Xing, R; Xu, Z; Zhang, H; Zhang, Y | 1 |
| Çelik, Y; Maden, M; Pamuk, G; Ünlü, E | 1 |
| Appelbaum, FR; Erba, H; Estey, E; Godwin, J; Mukherjee, S; Othus, M; Petersdorf, S; Sekeres, MA | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Miglino, M; Minetto, P; Pastori, G; Rebesco, B; Sessarego, M | 1 |
| Amador-Barciela, ML; Barrios, M; Benavente, C; Bergua, JM; Fernández-Abellán, P; García, R; García-Huerta, AJ; Herrera-Puente, P; Martinez-Cuadrón, D; Martínez-Sánchez, MP; Montesinos, P; Pérez-Encinas, M; Prieto-Fernandez, J; Riaza-Grau, R; Rodríguez-Macias, G; Rodríguez-Veiga, R; Sanz, MA; Sayas, MJ; Serrano, J; Simiele, A | 1 |
| Adam, H; Colle, J; Costello, R; Fanciullino, R; Farnault, L; Ivanov, V; Labiad, Y; Mercier, C; Suchon, P; Venton, G | 1 |
| Fang, J; Hong, M; Hu, Y; Li, W; Nie, D; Wang, H; Wu, Q; Xia, L; You, Y; Zhang, R; Zhong, Z | 1 |
| Laskowska, J; Lewandowska-Bieniek, J; Styczyński, J; Szczepanek, J; Tretyn, A | 1 |
| Aoi, M; Kitamura, K; Sakurada, H; Sugimura, Y; Tachi, T; Teramachi, H; Yamamura, M; Yuge, M | 1 |
| Chen, Y; Hu, J; Liu, T; Yang, T; Yang, X; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Suo, SS; Tong, HY; Wei, JY; Yao, XM; Yu, WJ; Zhang, Y; Zhu, SL | 1 |
| Andreeff, M; Borthakur, G; Brandt, M; Cortes, J; Daver, N; DiNardo, C; Estrov, Z; Garcia-Manero, G; Huang, X; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Pierce, S; Ravandi, F; Wang, S; Wang, X | 1 |
| Ding, K; Fu, R; Li, L; Liu, H; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y | 1 |
| Fridle, C; Manz, MG; Medinger, M; Pabst, T; Passweg, J; Seipel, K; Wilk, MC | 1 |
| Andreeff, M; Borthakur, G; Piya, S | 1 |
| Beltrão, EI; Benicio, MT; Bezerra, MA; Bezerra, MF; Coelho-Silva, JL; Lucena-Araujo, AR; Machado, CG; Nascimento, JC; Rego, EM; Rocha, CR | 1 |
| Chia, WK; Julia, MI; Leong, CF; Salwati, S; Tang, YL; Wong, CL; Yap, EC | 1 |
| Fischer, M; Fleischmann, M; Hilgendorf, I; Hochhaus, A; Schnetzke, U; Scholl, S; Spies-Weisshart, B; Walther, M | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Bergeron, M; Blonquist, TM; Brunner, AM; Burke, M; Chen, YB; Connolly, C; Fathi, AT; Fishman, KM; Foster, J; Graubert, TA; Hermance, NM; Hobbs, G; Joseph, C; Manning, AL; McGregor, KL; Neuberg, DS; Perry, AM; Ramos, AY; Sadrzadeh, H; Silver, R; Som, TT; Supko, J; Wander, SA | 1 |
| Clavio, M; Gobbi, M; Guolo, F; Lemoli, RM; Miglino, M; Minetto, P | 1 |
| Hayakawa, M; Ichihashi, T; Iida, H; Iino, M; Kiyoi, H; Naoe, T; Narimatsu, H; Sawamoto, A; Sugiura, I; Suzuki, R; Takeo, T; Tsuzuki, M; Yanada, M; Yokozawa, T | 1 |
| Baker, N; Bosi, A; Dansey, R; Herrmann, R; Kassis, J; Lazzarino, M; Noga, SJ; Sierra, J; Szer, J; Thomas, X | 1 |
| Candoni, A; Chiarvesio, A; Damiani, D; Fanin, R; Malagola, M; Martinelli, G; Michelutti, A; Piccaluga, PP; Russo, D; Simeone, E; Tiribelli, M; Toffoletti, E | 1 |
| Brandt, M; Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; Medeiros, LJ; O'Brien, S; Pierce, S; Tsimberidou, AM; Wen, S | 1 |
| Ito, T; Nakazawa, H; Saida, T; Uhara, H | 1 |
| Fladmark, KE; Gjertsen, BT; Hovland, R; Oveland, E; Selheim, F; Wergeland, L | 1 |
| Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Verstovsek, S; Wierda, W | 1 |
| Asagoe, K; Matsuzawa, Y; Sakoda, H; Sugahara, H; Togashi, Y | 1 |
| Corallo, CE; Coutsouvelis, J | 1 |
| Bordessoule, D; Contentin, N; de Revel, T; Dombret, H; Etienne, A; Gardin, C; Malfuson, JV; Rigaudeau, S; Terré, C; Thomas, X; Turlure, P; Vey, N | 1 |
| Belloc, F; Jeanneteau, M; Lacombe, F; Mahon, FX; Milpied, N; Pigneux, A; Reiffers, J; Uhalde, M | 1 |
| Borthakur, G; Estey, EH; Faderl, S; Gandhi, VV; Garcia-Manero, G; Kantarjian, H; Pierce, S; Plunkett, WK; Ravandi, F; Wang, X | 1 |
| Fujita, N; Inaba, T; Nakatani, T; Nishimura, H; Saito, J; Uchiyama, H; Yamamoto, M; Yamane, Y | 1 |
| Ando, K; Kawada, H; Murayama, H; Nakamura, N; Ogawa, Y; Ohmachi, K; Suzuki, R; Tsuboi, K | 1 |
| Jones, RL; Kulkarni, S; Mehta, J; Morgan, G; Potter, M; Powles, R; Saso, R; Singhal, S; Sirohi, B; Smith, K; Swansbury, GJ; Treleaven, J | 1 |
| Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B | 1 |
| Alexander, C; Bashford, J; Jefferies, PD; Lee, GA; Whitehead, K | 1 |
| Demir, M; Oztürk, E; Pamuk, GE; Taşçi, M | 1 |
| Bellaaj, H; Elloumi, M; Kallel, C; Kammoun, H; Kassar, O; Sandi, HS | 1 |
| Cafro, AM; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Nosari, AM; Ricci, F; Tedeschi, A | 1 |
| Bae, SH; Joo, YD; Kim, H; Lee, JH; Lee, KH; Lee, WS; Mo Ryoo, H; Park, JH | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Palmieri, S; Pedata, M; Viola, A | 1 |
| Chen, LJ; Li, JY; Lu, H; Lu, RN; Qian, SX; Qiu, HX; Sheng, RL; Wu, HX; Xu, W | 1 |
| Buyukasik, Y; Goker, H; Ozcebe, OI; Sayinalp, N; Serefhanoglu, S | 1 |
| Hong, M; Li, JY; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R | 1 |
| Darzynkiewicz, Z; Halicka, HD; Jayabose, S; Kajstura, M; Levendoglu-Tugal, O; Ozkaynak, MF; Sandoval, C; Seiter, K; Traganos, F | 1 |
| Bommana, V; Irani, F; Kasmani, R; Kumar, B; Mahajan, K; Mian, A | 1 |
| Cho, D; Kim, HJ; Kim, SH; Kim, TS; Lee, IK; Song, JH | 1 |
| Barbarroja, N; Carretero, RM; López-Pedrera, C; Lopez-Sanchez, LM; Luque, MJ; Rodriguez-Ariza, A; Torres, A; Torres, LA; Valverde-Estepa, A; Velasco, F | 1 |
| Copia, C; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Musto, P; Palmieri, S; Pedata, M; Riccardi, C | 1 |
| Abebe, L; Einzig, A; Lee, SH; Paietta, E; Wiernik, PH | 1 |
| Ahn, JS; Chae, YS; Cho, YY; Choi, YJ; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Lee, SR; Shin, HJ; Sohn, SK; Yang, DH | 1 |
| Candoni, A; Fanin, R; Malagola, M; Russo, D; Simeone, E; Tiribelli, M | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Abboud, CN; Augustin, KM; Cashen, AF; Dipersio, JF; Goyal, S; Hladnik, L; Martin, MG; Monahan, RS; Reichley, RM; Stockerl-Goldstein, K; Tiwari, D; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Bhuiyan, H; Bogason, A; Gruber, A; Masquelier, M; Paul, C; Vitols, S | 1 |
| Cotta, CV; Khan, G; Pohlman, B; Sweetenham, J; Wesolowski, R | 1 |
| Matsumura, I | 1 |
| Miyazaki, Y | 1 |
| Hong, M; Li, JY; Lu, H; Qian, SX; Wu, HX; Xu, W | 1 |
| Imanishi, D; Imoto, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Miyazaki, Y; Morita, Y; Naoe, T; Ohnishi, K; Ohno, R; Tanimoto, M; Yagasaki, F | 1 |
| Bordessoule, D; Bourhis, JH; Castaigne, S; Chevret, S; Contentin, N; Corm, S; de Revel, T; Dombret, H; Fenaux, P; Gardin, C; Merabet, F; Michallet, M; Pautas, C; Preudhomme, C; Raffoux, E; Reman, O; Rousselot, P; Terré, C; Thomas, X; Turlure, P | 1 |
| Ahn, HS; Cho, B; Chung, NG; Hwang, TJ; Im, HJ; Kang, HJ; Kim, HK; Koo, HH; Kook, H; Lee, DH; Park, HJ; Seo, JJ; Shin, HY; Sung, KW; Yoo, KH | 1 |
| Asou, N; Handa, H; Kageyama, S; Kishimoto, Y; Kiyoi, H; Maeda, Y; Matsuda, S; Miyawaki, S; Miyazaki, Y; Nagai, T; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Okada, M; Okumura, H; Takahashi, M; Takeuchi, J; Yagasaki, F | 1 |
| Dessalvi, P; Di Tucci, AA; Emanuele, A; Pettinau, M; Romani, C | 1 |
| Cho, EK; Lee, JH; Park, J; Shin, DB; Sym, SJ; Yi, HS | 1 |
| Bencini, S; Bosi, A; Gianfaldoni, G; Longo, G; Mannelli, F; Ponziani, V; Vannucchi, AM | 1 |
| Li, Y; Zhang, R; Zhang, XH | 1 |
| Cetin, CB; Ergene, U; Ozbalci, D | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Muccioli, G; Palmieri, S; Pane, F; Riccardi, C; Viola, A | 1 |
| Aziz, A; Gosbell, IB; Sanghavi, R; Varghese, B | 1 |
| Andreeff, M; Bekele, BN; Borthakur, G; Brandt, M; Byrd, A; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, HM; Konopleva, MY; Levis, M; Luthra, R; O'Brien, S; Pierce, SR; Pratz, K; Ravandi, F; Thomas, D | 1 |
| Chuang, MH; Li, DK; Yang, SC | 1 |
| Adiguzel, U; Erkayhan, G; Sari, A; Unal, S | 1 |
| Kato, J; Mori, T; Murata, M; Okamoto, S; Ono, Y; Shimizu, T; Sugita, K; Yamane, A | 1 |
| Betts, DR; Bourquin, JP; Bradtke, J; Creutzig, U; Dworzak, MN; Haas, OA; Reinhardt, D; Sander, A; Stary, J; von Neuhoff, C; Zemanova, Z; Zimmermann, M | 1 |
| Egorin, MJ; Espinoza-Delgado, I; Ferrajoli, A; Garcia-Manero, G; Holleran, JL; Kadia, TM; Kantarjian, HM; Madden, TL; Maddipotti, S; Newsome, W; Ravandi, F; Sanchez-Gonzalez, B; Schroeder, C; Thomas, DA; Yang, H; Zwiebel, JA | 1 |
| Bene, MC; Berthou, C; Cahn, JY; Dreyfus, F; Escoffre-Barbe, M; Fegueux, N; Harousseau, JL; Himberlin, C; Hunault-Berger, M; Ifrah, N; Jourdan, E; Lioure, B; Lissandre, S; Luquet, I; Milpied, N; Pigneux, A; Recher, C; Reiffers, J; Sauvezie, M; Witz, F | 1 |
| Choi, MJ; Kim, HO; Kim, HS; Park, YM | 1 |
| Bay, JO; Béné, MC; Bernard, M; Bouscary, D; Bulabois, CE; Chevallier, P; Daliphard, S; Delain, M; Fegueux, N; Fornecker, L; Harousseau, JL; Himberlin, C; Ifrah, N; Lioure, B; Luquet, I; Pigneux, A; Recher, C; Turlure, P; Vey, N; Witz, B | 1 |
| Elonen, E; Itälä-Remes, M; Jantunen, E; Kinnunen, U; Koistinen, P; Nousiainen, T; Ohtonen, P; Räty, R; Remes, K; Silvennoinen, R; Syrjälä, H | 1 |
| Bae, JY; Kim, BK; Kim, HK; Kim, I; Koh, Y; Lee, DS; Park, MH; Park, S; Park, SS; Song, EY; Yoon, SS | 1 |
| Andresen, S; Bolwell, B; Chan, J; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J; Tench, S | 1 |
| Fong, C; Tong, M | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Aytac, S; Balci, YI; Cetin, M; Gumruk, F; Gurgey, A; Kuskonmaz, B; Tavil, B; Tuncer, M; Uckan, D; Unal, S; Yetgin, S | 1 |
| Allen, S; Galinsky, I; Hurd, D; Kolitz, JE; Larson, RA; Marcucci, G; Moser, B; Sanford, B; Schulman, P; Stock, W; Stone, RM; Vij, R | 1 |
| Asou, N; Fujieda, A; Fujita, H; Handa, H; Honda, S; Kimura, Y; Kiyoi, H; Miyamura, K; Miyawaki, S; Miyazaki, Y; Nagai, T; Nakaseko, C; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Okumura, H; Sakamaki, H; Shinagawa, K; Takahashi, M; Taniwaki, M; Usui, N; Yagasaki, F; Yamane, T | 1 |
| Jeraj, R; Juckett, MB; Nickles, RJ; Perlman, SB; Vanderhoek, M | 1 |
| Andreeff, M; Borthakur, G; Byrd, AL; Carter, BZ; Estey, E; Kantarjian, H; Konopleva, M; Mak, DH; Morris, SJ | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wright, JJ | 1 |
| Appelbaum, FR | 1 |
| Abrahamsson, J; Forestier, E; Hasle, H; Heldrup, J; Jahnukainen, K; Jónsson, OG; Lausen, B; Palle, J; Zeller, B | 1 |
| Farah, RA; Farhat, HZ; Jalkh, KS; Kadri, AM; Sayad, PE | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ | 1 |
| Akiyama, N; Ayabe, T; Kawasugi, K; Nishi, R; Oka, Y; Shirafuji, N; Shirasaki, R; Shirota, M; Taguchi, A; Tashiro, H; Umezawa, K | 1 |
| Amri, A; Arguello, M; Borden, K; Cormack, G; Kraljacic, BC | 1 |
| Andrews, C; Baer, MR; Barcos, M; Baumann, H; Block, AW; Ford, LA; Nowak, NJ; Sait, SN; Tighe, S; Wang, ES; Wetzler, M | 1 |
| Baer, MR; Barcos, M; Block, AW; Ford, LA; Hyland, AJ; Licht, AS; Sait, SN; Varadarajan, R; Wang, ES; Wetzler, M | 1 |
| Bastida, J; Carretero, G; Medina, C; Santana, N; Valerón-Almazán, P; Vilar, J | 1 |
| Dobashi, N; Fujita, H; Kiyoi, H; Kobayashi, Y; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Ohnishi, K; Ohtake, S; Ohwada, C; Sakura, T; Shigeno, K; Takeshita, A; Usui, N; Yahagi, Y | 1 |
| Baer, MR; Ball, ED; Borthakur, G; Cortes, J; Dipersio, J; Fernandez, HF; Goodman, M; Kantarjian, H; Kolitz, JE; Wetzler, M | 1 |
| Bozoglan, H; Ergene, U; Yoleri, L | 1 |
| Solis, EC | 1 |
| Katayama, Y; Murayama, SY; Myoken, Y; Sugata, T | 1 |
| Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
| Barroso, RS; Chauffaille, ML; Ribeiro, JC; Sandes, AF; Silva, MR | 1 |
| Baer, MR; Barcos, M; Block, AW; Ford, LA; Hyland, AJ; Lee, HJ; Licht, AS; Sait, SN; Wang, ES; Wetzler, M | 1 |
| Baro, J; Bermúdez, A; Colorado, M; Conde, E; Díez-Gallarreta, Z; Gutiérrez, ML; Insunza, A; Iriondo, A; López-Duarte, M; Olalla, I; Pérez-Vázquez, G; Richard, C; Sanroma, P; Yañez, L | 1 |
| Andreeff, M; Brandt, M; Cortes, J; Faderl, S; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Kornblau, S; Luthra, R; Patel, K; Pierce, S; Ravandi, F; Wang, X | 1 |
| Cho, JH; Hur, M; Kim, WS; Ko, YS; Lee, MH; Moon, HW; Yun, YM | 1 |
| Fang, LW; Hu, NB; Pan, LJ; Qin, TJ; Wang, JZ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Bertoli, S; Cavelier, C; Creancier, L; Dastugue, N; Delabesse, E; Demur, C; Dobbelstein, S; Huguet, F; Huynh, A; Kruczynski, A; LaRochelle, O; Mansat-De Mas, V; Pillon, A; Récher, C; Sarry, A; Sarry, JE; Strzelecki, AC; Vergez, F | 1 |
| Giles, F; Jacobsen, TF; O'Brien, S; Ravandi, F; Rizzieri, D; Swords, R | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Cheong, JW; Kim, JS; Kim, SJ; Kim, Y; Min, YH; Yoon, S | 1 |
| Alonzo, TA; Chaleff, S; Chang, M; Dahl, G; Hurwitz, CA; Weinstein, H | 1 |
| Huang, TS; Lin, HW; Shih, SR; Yao, M | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Abbenante, MC; Astolfi, A; Baccarani, M; Candoni, A; Cattina, F; Damiani, D; Fanin, R; Ferrari, A; Formica, S; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Lonetti, A; Malagola, M; Martinelli, G; Michelutti, A; Ottaviani, E; Papayannidis, C; Parisi, S; Russo, D; Sazzini, M; Simeone, E | 1 |
| Bekele, NB; Borthakur, G; Brandt, M; Cortes, JE; de Lima, M; Faderl, S; Garcia-Manero, G; Hu, Y; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, MY; McCue, D; Newsome, WM; Pierce, SR; Ravandi, F; Tambaro, FP; Yang, H | 1 |
| Ahn, KS; Kim, IW; Kim, KI; Kim, TK; Oh, JM; Shin, WG; Yoon, SS | 1 |
| Avery, S; Coutsouvelis, J; Lee, D; Low, M; Opat, S; Patil, S; Salem, H; Schwarer, A; Spencer, A; Walker, P; Wei, A | 1 |
| Rashidi, A; Roullet, MR | 1 |
| de Revel, T; Eddou, H; Foissaud, V; Konopacki, J; Malfuson, JV; Thepenier, C | 1 |
| Creutzig, U; Reinhardt, D; Sander, A; Von Neuhoff, C | 1 |
| Ahn, HK; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, KH; Kim, SH; Kim, YK; Lee, KO; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, CH; Park, J; Sohn, SK | 1 |
| Damante, G; Damiani, D; Fabbro, D; Fanin, R; Franzoni, A; Tiribelli, M | 1 |
| Cheong, JW; Hong, DS; Joo, YD; Kim, BK; Kim, CS; Kim, DY; Kim, H; Kim, I; Kim, MK; Kim, SH; Koh, Y; Lee, HK; Lee, JH; Lee, KH; Lee, SM; Min, YH; Park, E; Park, MR; Park, S; Park, SK; Sohn, SK; Won, JH; Yoon, SS | 1 |
| Garcia-Manero, G | 1 |
| Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
| Abrahamsson, J; Forestier, E; Gustafsson, B; Ha, SY; Hasle, H; Heilmann, C; Heldrup, J; Jahnukainen, K; Jónsson, ÓG; Lausen, B; Palle, J; Wareham, NE; Zeller, B | 1 |
| Boissel, N; Bordessoule, D; Castaigne, S; Celli-Lebras, K; Chevret, S; de Botton, S; de Revel, T; Dombret, H; Fenaux, P; Gachard, N; Gardin, C; Pautas, C; Preudhomme, C; Quesnel, B; Raffoux, E; Renneville, A; Terré, C; Thomas, X; Turlure, P | 1 |
| Chen, F; Fan, Z; Feng, R; Guo, X; Huang, F; Liu, X; Meng, F; Shi, P; Xu, B; Zha, J | 1 |
| Attal, M; Bérard, E; Bertoli, S; Dastugue, N; Delabesse, E; Demur, C; Dobbelstein, S; Duchayne, E; Huguet, F; Huynh, A; Laurent, G; Lauwers-Cances, V; Mansat-De Mas, V; Récher, C; Sarry, A; Tavitian, S; Vergez, F | 1 |
| Andre, V; Andreeff, M; Brandt, JT; Callies, S; Erba, HP; Juckett, M; Kadam, S; Lahn, M; Sayar, H; Schmidt, S; Van Bockstaele, D | 1 |
| Alonzo, TA; Beyene, J; Lehrnbecher, T; Leibundgut, K; Sung, L; Teuffel, O | 1 |
| Balcerska, A; Balwierz, W; Chybicka, A; Debski, R; Kowalczyk, J; Kurylak, A; Matysiak, M; Rokicka-Milewska, R; Sońta-Jakimczyk, D; Styczyński, J; Wachowiak, J; Wysocki, M | 1 |
| Hoagland, HC; Hogan, WJ; Kaufmann, SH; Letendre, L; Litzow, MR; Pruthi, RK; Tefferi, A | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Lockwood, L; Marshall, GM; O'Brien, TA; Oswald, CM; Rice, M; Russell, SJ; Shaw, PJ; Teague, L; Tiedemann, K; Vowels, MR | 1 |
| Wood, RA | 1 |
| Arlt, A; Bartscht, T; Bruhn, HD; Bruhn, T; Gieseler, F; Schiller, H; Seifert, A; Zahn, MO | 1 |
| Douglas, RS; Goldstein, SM; Nichols, C | 1 |
| Alvarado, Y; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A | 1 |
| Bolaños-Meade, J; Buddharaju, LN; Chen, TT; Guo, C; Karp, JE; Rapoport, AP; Sarkodee-Adoo, CB; Tidwell, ML | 1 |
| Dansako, H; Fujii, N; Fujita, S; Kaneda, K; Kojima, K; Shinagawa, K; Tanimoto, M; Yano, T; Yasukawa, M; Yoshida, C | 1 |
| Disis, ML; Ginsburg, AS; Salazar, LG; True, LD | 1 |
| Bacigalupo, A; Balleari, E; Ballerini, F; Beltrami, G; Canepa, L; Carella, AM; Carrara, P; Cerri, R; Clavio, M; Galbusera, V; Gatto, S; Ghio, R; Gobbi, M; Miglino, M; Pierri, I; Quintino, S; Risso, M; Sessarego, M; Varaldo, R; Venturino, C | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Auvrignon, A; Bastard, C; Blaise, D; Castaigne, S; Dastugue, N; Delaunay, J; Dombret, H; Fenaux, P; Fière, D; Harousseau, JL; Lamy, T; Leblanc, T; Leverger, G; Mugneret, F; Pigneux, A; Reiffers, J; Rigal-Huguet, F; Van den Akker, J; Vey, N; Witz, F | 1 |
| Go, RS; Johnston, KL | 1 |
| Buquicchio, C; Carluccio, P; Greco, G; Liso, A; Liso, V; Mestice, A; Pastore, D; Rizzi, R; Specchia, G | 1 |
| Beyan, C; Cetin, T; Kaptan, K; Nevruz, O | 1 |
| Creutzig, U; Griesinger, F; Hählen, K; Harbott, J; Huismans, DR; Kaspers, GJ; Meshinchi, S; Munske, L; Pieters, R; Podleschny, M; Radich, JP; Reinhardt, D; Veerman, AJ; Zimmermann, M; Zwaan, CM | 1 |
| Crum, NF; Fehl, FC; Graham, BS; Higginbottom, PA | 1 |
| Higa, T; Imai, A; Imamura, M; Kasai, M; Kiyama, Y; Kobayashi, N; Kondo, Y; Miyokawa, N; Ogasawara, M; Ogawa, T; Sato, K; Tanaka, J; Toubai, T | 1 |
| Kumagawa, M; Nagano, M; Suzuki, K; Suzumiya, J; Takamatsu, Y; Tamura, K | 1 |
| Boogaerts, M; Daenen, S; de Greef, G; Ferrant, A; Fey, M; Gmür, J; Gratwohl, A; Huijgens, P; Kovacsovics, T; Löwenberg, B; Schouten, H; Sonneveld, P; Theobald, M; van Putten, W; Verdonck, L | 1 |
| Debatin, KM; Eckhoff, S; Meyer, LH; Mohr, A; Stahnke, K | 1 |
| Balcerska, A; Balwierz, W; Chybicka, A; Dobaczewski, G; Dłuzniewska, A; Kowalczyk, J; Krenke, K; Lewandowska, D; Malinowska, I; Matysiak, M; Mikołajczyk, M; Niedźwiedzki, M; Rokicka-Milewska, R; Sońta-Jakimczyk, D; Stefaniak, J; Styczyński, J; Tomaszewska, R; Wachowiak, J; Wysocki, M | 1 |
| Boiron, JM; Boucheix, C; Bourhis, JH; Dhedin, N; Fière, D; Gallo, JH; Lhéritier, V; Reman, O; Rubio, MT; Thomas, X; Vernant, JP | 1 |
| Fuchigami, K; Fukushima, T; Hata, T; Honda, M; Jinnai, I; Kuriyama, K; Miyazaki, Y; Togami, K; Tomonaga, M; Yamasaki, J | 1 |
| Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Ronconi, S; Rondoni, M; Visani, G | 1 |
| Fujii, S; Kikuchi, T; Miyata, A | 1 |
| Almqvist, A; Anttila, P; Elonen, E; Jantunen, E; Koistinen, P; Koivunen, E; Koponen, A; Mikkola, M; Nousiainen, T; Oksanen, K; Pelliniemi, TT; Pulli, T; Remes, K; Ruutu, T; Sarkkinen, R; Silvennoinen, R; Timonen, T; Vanhatalo, S | 1 |
| Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G | 1 |
| Akercan, F; Cagirgan, S; Donmez, A; Mgoyi, L; Ozkinay, E; Vural, F; Yucebilgin, MS | 1 |
| Koyama, M; Matsuo, K; Murata, Y; Shimoya, K; Ueda, S; Wada, K | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S | 1 |
| Creutzig, U; Dworzak, M; Lehrnbecher, T; Reinhardt, D; Stary, J; Zimmermann, M | 1 |
| Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M | 1 |
| Maruyama, Y; Satoh, Y; Takahashi, T; Tsujisaki, M; Yoshimoto, M | 1 |
| Alymara, V; Bourantas, KL; Chaidos, A; Tsiara, S; Tzouvara, E; Vartholomatos, G | 1 |
| Balaian, L; Ball, ED | 1 |
| Beardell, F; Brunner, J; Capizzi, R; Cohn, J; Ferbér, A; Filicko, J; Flomenberg, N; Garcia-Manero, G; Grosso, D; Martinez, J; Mookerjee, B; Rose, L; Tice, D; Wagner, JL | 1 |
| Barulli, S; D'Adamo, F; Guiducci, B; Isidori, A; Leopardi, G; Malagola, M; Malerba, L; Mele, A; Nicolini, G; Piccaluga, P; Politi, P; Sparaventi, G; Stramigioli, S; Talevi, N; Visani, G | 1 |
| Borkhardt, A; Bruch, J; Fuchs, U; Metzler, M; Perez, AV; Wilda, M; Woessmann, W | 1 |
| Karp, JE; Smith, BD | 1 |
| Albitar, M; Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Kornblau, S; Mattiuzzi, GN; O'Brien, SM; Thomas, D; Tsimberidou, AM; Verstovsek, S; Wierda, W | 1 |
| Creutzig, U; Diekamp, S; Dworzak, M; Reinhardt, D; Stary, J; Zimmermann, M | 1 |
| Balestri, F; Biscardi, M; Budriesi, R; Caporale, R; Gavazzi, S; Grossi, A; Scappini, B; Teodori, E | 1 |
| Lamm, RD; McCarthy, PM; Sade, RM | 1 |
| Behar, C; Benoit, Y; Bertrand, Y; Boutard, P; Entz-Werle, N; Ferster, A; Hoyoux, C; Lutz, P; Margueritte, G; Norton, L; Otten, J; Pages, MP; Philippe, N; Plouvier, E; Rialland, X; Suciu, S; Thyss, A; Uyttebroeck, A; van der Werff ten Bosch, J; Vandecruys, E; Vilmer, E | 1 |
| Alpay, R; Disel, U; Paydas, S; Tuncer, I; Yavuz, S | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Schmidt-Wolf, IG; Schwerdtfeger, R | 1 |
| Jóźwiak, Z; Kowalczyk, A; Marczak, A; Robak, T; Wrzesień-Kus, A | 1 |
| Asou, N; Emi, N; Honda, S; Kishimoto, Y; Matsuda, S; Matsushima, T; Mitani, K; Miyawaki, S; Miyazaki, Y; Ogawa, Y; Ohno, R; Ohtake, S; Sakamaki, H; Takahashi, M; Yagasaki, F | 1 |
| Caballero, D; Mateos, JJ; Perez, E; San Miguel, JF; Sanz-Rodriguez, C; Vazquez, L | 1 |
| Du, X; Ke, XY; Liu, Y; Lü, JQ; Lu, ZS; Ma, J; Shen, ZX; Xu, XH; Zeng, XY; Zhan, ZM; Zhang, XH; Zhao, YM | 1 |
| Belch, A; Gluck, S; Larratt, L; Robinson, KS; Sheridan, D; Shustik, C; Stewart, K; Van Der Jagt, R; Wells, G; Yetisir, E | 1 |
| Hatoum, HA; Hudaib, AR; Mahfouz, RA; Otrock, ZK; Shamseddine, AI; Taher, AT | 1 |
| Meehan, SA; Polsky, D; Scharf, S; Srivastava, M | 1 |
| Appelbaum, FR; Banker, DE; Beran, M; Chen, W; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Jackson, CE; Kornblau, SM; Lemker, E; Shen, D; Stirewalt, D; Verstovsek, S | 1 |
| Du, X; Ke, XY; Liu, Y; Lu, ZS; Lv, JQ; Ma, J; Shen, ZX; Xu, XH; Zeng, XY; Zhan, ZM; Zhang, XH; Zhao, YM | 1 |
| Belloc, F; de Verneuil, H; Lacombe, F; Mahon, FX; Milpied, N; Moreau-Gaudry, F; Pigneux, A; Praloran, V; Reiffers, J; Uhalde, M | 1 |
| Bocchia, M; Bucalossi, A; Defina, M; Forconi, F; Gozzetti, A; Lauria, F; Pirrotta, MT | 1 |
| Alfaro, EM; Alonso, CN; Baro, C; Corral, Mdel P; Felice, MS; Gallego, MS; Rossi, J; Solé, F; Villa, O | 1 |
| Capelli, D; Discepoli, G; Leoni, P; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Troiani, E | 1 |
| Boveri, E; Castagnola, C; Castello, A; Magrini, U | 1 |
| Breda, L; Chiarelli, F; De Sanctis, S; Di Marzio, D; La Barba, G; Rollo, V | 1 |
| Caracciolo, F; Focosi, D; Galimberti, S; Papineschi, F; Petrini, M | 1 |
| Abruzzo, LV; Bobadilla, D; Cortes, J; Gibbons, DL; Kantarjian, H; Quintás-Cardama, A; Slovak, ML | 1 |
| Alonzo, TA; Arceci, RJ; Arndt, C; Barnard, DR; Dinndorf, P; Dusenbery, K; Feig, S; Feusner, J; Gerbing, RB; Heerema, NA; Lange, BJ; Luna-Fineman, S; Seibel, N; Shannon, K; Smith, FO; Weiman, M | 1 |
| Dastugue, N; Huguet, F; Ifrah, N; Jourdan, E; Perreau, V; Pigneux, A; Reiffers, J; Salmi, LR; Sotto, JJ; Vey, N | 1 |
| Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N | 1 |
| Dölken, G; Flieger, D; Glasmacher, A; Hahn-Ast, C; Kirchner, H; von Lilienfeld-Toal, M | 1 |
| Büchner, T; Creutzig, U; Döhner, H; Reinhardt, D; Sauerland, MC; Schlenk, RF; Zimmermann, M | 1 |
| Asai, T; Chiba, S; Hangaishi, A; Kurokawa, M; Suzuki, HI; Tamaki, Z | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; D'Amato, F; De Angelo, DJ; Galinsky, I; Levine, J; McAfee, S; Miller, KB; Neuberg, D; Schenkein, D; Sirulnik, A; Stone, RM; Supko, JG; Trehu, EG; Wadleigh, M; Zahrieh, D | 1 |
| Hwang, SY; Kim, HJ; Kim, SH; Kim, TS; Song, JH | 1 |
| Ağirbasli, H; Bilgen, H; Can, E; Cerikçioğlu, N; Durmaz, R; Gedikoğlu, G; Otlu, B; Ozcan, SK; Sinik, G; Sugita, T; Yalman, N | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Dardenne, M; de Witte, T; Fenaux, P; Hayat, M; Jaksic, B; Peetermans, M; Selleslag, D; Strijckmans, P; Suciu, S; Zittoun, R | 1 |
| Stolt, CM | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Anderlini, P; Andreeff, M; Benjamin, RS; Ewer, MS; Kantarjian, HM; Kornblau, SM; Mackay, B; O'Brien, S; Pierce, SA; Wong, FC | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Heimpel, H; Heit, W; Huber, C; Kolbe, K; Maschmeyer, G; Mitrou, PS | 1 |
| D'Onofrio, G; Di Mario, A; Etuk, B; Leone, G; Salutari, P; Sica, S | 1 |
| Cedrych, I; Hołowiecka, B; Hołowiecki, J; Kachel, L; Krawczyk, M; Krzemień, S; Rudzka, E; Wacławik, A; Wojciechowska, M; Wojnar, J | 1 |
| Aul, C; Burk, M; Gogolin, F; Heyll, A; Meckenstock, G; Runde, V; Söhngen, D; Winkelmann, M; Wolf, HH; Zahner, J | 1 |
| Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
| Belloc, F; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Lopez, F; Mahon, FX; Marit, G; Montastruc, M; Puntous, M | 1 |
| Kaletin, GI; Pirogova, NA; Volkova, MA | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohhashi, Y; Yamada, K | 1 |
| Berman, E | 2 |
| Estey, EH; Kantarjian, H; Keating, M | 1 |
| Cerutti, I; Fernández-Barbieri, MA; Gomel, M; Kvicala, R; Matus-Ridley, M; Negri-Aranguren, P; Rosso, A; Sackmann-Muriel, F; Santarelli, MT | 1 |
| Ariyoshi, Y; Ogawa, M | 1 |
| Carella, AM; Carlier, P; Iacopino, P; Liso, V; Mirto, S; Montillo, M; Pagano, L; Pungolino, E; Resegotti, L; Stasi, R | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Yamada, K | 2 |
| Estey, EH; Simon, RM; Thall, PF | 1 |
| Berman, E; Golde, DW; Maslak, PG; Scheinberg, DA; Tyson, D; Weiss, MA; Yao, TJ | 1 |
| Baldicchi, L; Corneo, GM; Mangiagalli, M; Miccolis, IR; Pioltelli, P; Pogliani, EM | 1 |
| Gibney, MD; Nelson-Adesokan, P; Penneys, NS | 1 |
| Falk, RE; Fuerst, MM; Giles, FJ; Kusuanco, DA; Lawrence, GN; Lim, SW; Look, RM | 1 |
| Bamberger, U; Esteban, M; Heckel, A; Kasimir-Bauer, S; Müller, MR; Scheulen, ME; Schröder, J; Seeber, S | 1 |
| Attal, M; Berthaud, P; Broustet, A; Danel, P; Fabères, C; Gastaut, JA; Hollard, D; Huguet, F; Hurteloup, P; Lepeu, G; Maraninchi, D; Marit, G; Mercier, M; Michallet, M; Molina, L; Pris, J; Reiffers, J; Stoppa, AM; Tellier, Z | 1 |
| Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G | 1 |
| Gieseler, F; Glasmacher, A; Kämpfe, D; Kunze, J; Nuessler, V; Valsamas, S; Wandt, H; Wilms, K | 2 |
| Kearns, P; Majumdar, G; Partridge, F; Richardson, W; Wilcox, R | 1 |
| Estey, E; Kuschel, B | 1 |
| Audhuy, B; Baranger, L; Berthaud, P; Berthou, C; Briere, J; Cahn, JY; Caillot, D; Casassus, P; Desablens, B; Francois, S; Guyotat, D; Harousseau, JL; Herve, P; Hurteloup, P; Leprise, PY; Linassier, C; Lioure, B; Pignon, B; Polin, V; Sadoun, A; Vilque, JP; Witz, F | 1 |
| Dardenne, M; De Witte, T; Hayat, M; Kurstjens, R; Labar, B; Muus, P; Ribeiro, M; Roozendaal, K; Selleslag, D; Solbu, G; Suciu, S; Zittoun, R | 1 |
| Clark, M; Gieseler, F; Glasmacher, A; Kämpfe, D; Kunze, J; Valsamas, S; Zernak, C | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohashi, Y; Yamada, K | 1 |
| Chen, TP; Chen, TY; Chen, YC; Lin, SF; Tsao, CJ; Yao, M | 1 |
| Ahn, HS; Cho, KS; Choi, YM; Chung, TJ; Hwang, TJ; Kim, CC; Kim, DW; Kim, HJ; Kim, HK; Kim, HS; Kim, JS; Lee, KS; Park, HS; Park, JW; Song, HS | 1 |
| Kidd, P; Quien, ET; Saidi, P; Sandhaus, L; Strair, R; Wallach, B | 1 |
| Chaibi, P; de Revel, T; Dombret, H; Gardin, C; Micléa, JM; Nédellec, G; Rousselot, P; Turlure, P | 1 |
| Degenhardt, F; Ganser, A; Geissler, RG; Hertenstein, B; Karthaus, M; Prahst, A | 1 |
| Abenhardt, W; Diem, H; Gieseler, F; Gullis, E; Kolb, HJ; Langenmayer, I; Nüssler, V; Pelka-Fleischer, R; Schmitt, R; Wilmanns, W; Wohlrab, A; Zwierzina, H | 1 |
| Glasmacher, A; Gorschlüter, M; Klehr, HU; Klein, B; Mezger, J; Risse, F | 1 |
| Borecky, DJ; Keeling, JH; Stephenson, JJ; Vukelja, SJ | 1 |
| Elonen, E; Hänninen, A; Järventie, G; Kätkä, K; Koistinen, P; Koivunen, E; Nousiainen, T; Oksanen, K; Pelliniemi, TT; Remes, K; Ruutu, T; Timonen, T; Volin, L | 1 |
| Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| Björkholm, M; Eksborg, S; Fagerlund, E; Hast, R | 1 |
| Campbell, J; De La Serna, J; Diaz-Mediavilla, J; Francisco Tomás, J; García de Paredes, ML; Grande, C; Solano, C | 1 |
| Daibata, M; Ido, E; Kubonishi, I; Kuzume, T; Miyoshi, I; Murakami, K; Taguchi, H | 1 |
| Hall, JL; Hamblin, TJ; Myint, H; Ross, FM | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Rayon, C | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M | 1 |
| Fukushima, T; Ueda, T | 1 |
| Alfaro, E; Casak, S; Cygler, A; Felice, MS; Fraquelli, L; Gallego, M; Pérez, LE; Quinteros, R; Sackmann-Muriel, F; Zubizarreta, P | 1 |
| Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D; Zaja, F | 1 |
| Fusaoka, T; Kataoka, A; Tunamoto, K; Wakazono, Y | 1 |
| Akan, H; Arat, M; Arslan, O; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Clarridge, J; Nachamkin, I; Osborne, J; Patel, JB; Schuster, MS; Waddington, M | 1 |
| Loy, BA; Martin, AW; Tecimer, C | 1 |
| Ballerini, F; Beltrami, G; Canepa, L; Carrara, P; Cavaliere, M; Celesti, L; Clavio, M; Gatto, S; Gobbi, M; Lanza, L; Miglino, M; Pierri, I; Pietrasanta, D; Quintino, S; Varese, P | 1 |
| Benito, L; Delgado, I; García Alonso, L; García Vela, JA; Martin, M; Monteserin, MC; Oña, F; Somolinos, N | 1 |
| Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D | 1 |
| de Witte, T; Pennings, AH; Raymakers, RA; Smeets, ME; Vierwinden, G; Wessels, H | 1 |
| Filipits, M; Geissler, K; Jäger, U; Lechner, K; Pirker, R; Pohl, G; Scheper, RJ; Stranzl, T; Suchomel, RW | 1 |
| Ağaoğlu, L; Anak, S; Erdem, S; Gedikoğlu, G; Hacibektaşoğlu, A; Karakaş, Z | 1 |
| Diehl, V; Dimski, T; Lathan, B; Pantke, B; Schinköthe, T; Staib, P; Voliotis, D; Wiedenmann, S | 1 |
| Leone, G; Pagano, L; Sica, S | 1 |
| Archimbaud, E; Assouline, D; Belhabri, A; Blanc, M; Fière, D; Michallet, M; Thomas, X; Tigaud, JD; Troncy, J; Wattel, E | 1 |
| Hinrichs, SH; Iwen, PC; Lackner, RP; McCarthy, DI; Rinaldi, MG; Sigler, L; Sutton, DA; Tarantolo, S | 1 |
| Kasimir-Bauer, S; Scheulen, ME; Schröder, JK; Seeber, S | 1 |
| Behnisch, W; Bender-Götze, C; Creutzig, U; Graf, N; Hermann, J; Kabisch, K; Körholz, D; Mann, G; Niemeyer, CM; Reiter, A; Ritter, J; Scheel-Walter, H; Zimmermann, M | 1 |
| Hatake, K; Imagawa, S; Izumi, T; Komatsu, N; Miura, Y; Miyasato, A; Muroi, K; Nagashima, T; Ozawa, K; Uchida, M; Yoshida, M | 1 |
| Aloe Spiriti, MA; Betrò, P; Breccia, M; D'Elia, GM; Latagliata, R; Luzi, G; Montefusco, E; Petti, MC; Pulsoni, A; Spadea, A | 1 |
| Fujii, S; Fukushi, Y; Futagami, M; Higuchi, T; Saito, Y; Sakamoto, T; Sato, S; Takami, H; Yokoyama, Y | 1 |
| Kajiguchi, T; Miyata, Y; Saito, M; Takeyama, H | 1 |
| de Witte, T; Preijers, F; Schaap, N; Schattenberg, A; van der Maazen, R | 1 |
| Beelen, DW; Brittinger, G; Flasshove, M; Kemmeries, G; Meusers, P; Noppeney, R; Roggenbuck, U; Scheulen, ME; Schütte, J; Seeber, S; Sohrab, S | 1 |
| Adriansson, M; Arheden, K; Axelsson, P; Billström, R; Cervin, A; Fioretos, T; Johansson, B; Mitelman, F; Olofsson, T; Strömbeck, B; Tanke, HJ | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Hatake, K; Komatsu, N; Matsumoto, Y; Mori, M; Muroi, K; Ohtsuki, T; Ozawa, K | 1 |
| Boos, J; Creutzig, U; Feldges, A; Gadner, H; Hermann, J; Kühl, J; Niemeyer, CM; Ritter, J; Sawatzki, DB; Schwabe, D; Selle, B; Zimmermann, M | 1 |
| Douglas, R; Michael, B; Nabil, S; Thomas, F | 1 |
| Berthold, F; Creutzig, U; Gadner, H; Havers, W; Henze, G; Hermann, J; Jürgens, H; Kabisch, H; Kluba, U; Niggli, F; Reinhardt, D; Reiter, A; Ritter, J; Zimmermann, M | 1 |
| Bardy, P; Horvath, N; Hughes, T; Hui, CH; To, LB | 1 |
| Bessho, M; Hirashima, K; Kawai, N; Kayano, H; Kusumoto, S; Matsuda, A; Sakata, T; Sugahara, Y; Suzuki, T; Yagasaki, F; Yoshida, K | 1 |
| Amadori, S; Archimbaud, E; Aul, C; Boogaerts, M; de Witte, T; Ferrant, A; Gratwohl, A; Hagemeijer, A; Jehn, U; Labar, B; Mandelli, F; Muus, P; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R; Zwierzina, H | 1 |
| Gotto, H; Hartmann, F; Jacobs, G; Pfreundschuh, M; Schwamborn, J | 1 |
| Gadner, H; Mann, G; Trebo, MM | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Heller, G | 1 |
| Hahn, JS; Jang, JH; Ko, YW; Lee, ST; Min, YH; Suh, HC | 1 |
| Iwato, K; Kyo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suetsugu, Y; Sugihara, T; Wada, H; Yamada, O; Yata, K; Yawata, Y | 1 |
| Alkotob, LM; Avery, RK; Chemaly, RF; Eliachar, I; Fox, SB; Procop, GW; Scharpf, J; Schmitt, SK; Smith, M; Sobecks, R | 1 |
| Bernstein, SH; Jusko, WJ; Krzyzanski, W; Nichol, J; Wetzler, M | 1 |
| Chan-Lam, D; Copplestone, JA; Johnson, S; Phillips, M; Prentice, A; Price, R | 1 |
| Boogen, C; Lennartz, K; Müller, MR; Nowrousian, MR; Rajewsky, MF; Seeber, S | 1 |
| Di Mario, A; Etuk, B; Leone, G; Pagano, L; Salutari, P; Sica, S | 1 |
| Cersosimo, RJ | 1 |
| Resegotti, L | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
| Berman, E; McBride, M | 1 |
| Banks, PL; Bartolucci, AA; Flaum, MA; Gerber, MC; Omura, GA; Velez-Garcia, E; Vogler, WR; Weiner, RS | 1 |
| Arlin, ZA; Banks, PL; Case, DC; Enck, RE; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Ardia, A; Di Pietro, N; Di Raimondo, F; Falconi, E; Ganzina, F; Geraci, E; Ladogana, S; Latagliata, R; Mandelli, F; Petti, MC | 1 |
| Hanrahan, A; Lobo, PJ; Powles, RL; Reynold, DK | 1 |
| Baccarani, M; Cenacchi, A; Damiani, D; Fanin, R; Fogli, M; Gamberi, B; Revignas, G; Russo, D; Tura, S; Visani, G | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, S; Kolitz, J; McKenzie, S; Santorsa, J | 1 |
| Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J | 1 |
| Barbui, T; Biondi, A; Catapano, C; D'Incalci, M; Giudici, G; Limonta, M; Masera, G; Specchia, G | 1 |
| Buscarini, L; Cavanna, L; Civardi, G; Di Stasi, M; Fornari, F; Moretto, M; Sbolli, G | 1 |
| Berrebi, A; Polliack, A | 1 |
| Chapuis, B; Grob, JP; Helg, C; Pugin, P | 1 |
| Hansen, NE; Karle, H; Keldsen, N; Nissen, NI | 1 |
| Boschetti, C; Cofrancesco, E; Cortellaro, M; Moreo, G; Pogliani, E; Salvatore, M | 1 |
| Carella, AM; D'Amico, T; Damasio, E; Gaozza, E; Giordano, D; Nati, S; Piatti, G; Pungolino, E; Spriano, M | 1 |
| Dufour, P; Facon, T; Guy, H; Harousseau, JL; Hurteloup, P; Ifrah, N; Milpied, N; Reiffers, J; Rigal-Huguet, F | 1 |
| Haanen, C; Minderman, H; Speth, PA | 1 |
| Omura, G; Raney, M; Velez-Garcia, E; Vogler, WR | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Lazzarino, M; Merante, S; Morra, E | 1 |
| Andreeff, M; Berman, E; Clarkson, BD; Gabrilove, J; Gee, TS; Gulati, S; Kempin, SJ; Raymond, V; Wiernik, PH; Young, CW | 1 |
| Carella, AM; Cerri, R; Giordano, D; Nati, S; Piatti, G; Pungolino, E; Risso, M | 1 |
| Guy, H; Harousseau, JL; Hurteloup, P; Milpied, N; Pris, J; Rigal-Huguet, F | 1 |
| Annaloro, C; Cortelezzi, A; Cortellaro, M; Della Volpe, A; Lambertenghi-Deliliers, G; Maiolo, AT; Mozzana, R; Pogliani, E; Polli, EE; Pozzoli, E | 1 |
| Mandelli, F; Petti, MC | 1 |
| Arlin, ZA; Case, DC; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW | 1 |
| Löwenberg, B; Schölzel, C; van Putten, W | 1 |
| Fülle, HH; Hellriegel, KP | 2 |
| Carcassonne, Y; Dufour, P; Harousseau, JL; Hayat, M; Hurteloup, P; Jaubert, J; Le Prise, PY; Monconduit, M; Reiffers, J; Rigal-Huguet, F | 1 |
| Harousseau, JL; Huet, S; Hurteloup, P; Pris, J; Reiffers, J; Rigal-Huguet, F; Robert, J; Tamassia, V | 1 |
| Bayle, C; Berger, R; Carde, P; Finaud, M; Hayat, M; Hurteloup, P; Morardet, N; Parmentier, C; Schlumberger, M | 1 |
49 review(s) available for idarubicin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Is there an optimal adjunct therapy to traditional cytotoxic induction?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction | 2021 |
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2023 |
Leukemic Vasculitis: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow Transplantation; Colitis, Ulcerative; Cytarabine; Diagnosis, Differential; Erythema; Female; Humans; Idarubicin; Immunohistochemistry; Leg Dermatoses; Leukemia, Myeloid, Acute; Leukemic Infiltration; Mesalamine; Skin Neoplasms; Transplantation Conditioning; Treatment Outcome; Vasculitis | 2019 |
Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cladribine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2020 |
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Safety; Survival Analysis; Topoisomerase II Inhibitors; Treatment Outcome; United States; Young Adult | 2020 |
How I treat older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous | 2018 |
Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Odds Ratio; Remission Induction; Treatment Outcome; Young Adult | 2018 |
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2019 |
Topoisomerase II inhibitors in AML: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Salvage Therapy; Topoisomerase II Inhibitors | 2019 |
Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Publication Bias; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Development of a curative treatment within the AML-BFM studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Methotrexate; Multicenter Studies as Topic; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thioguanine; Vincristine | 2013 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
[Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Discovery; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Mutation; Recurrence; Tretinoin; Vincristine | 2014 |
Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Brain; Cerebral Hemorrhage; Cytarabine; Fatal Outcome; Humans; Hydroxamic Acids; Idarubicin; Interleukin-2 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mast Cells; Middle Aged; Neoplasms, Second Primary; Neoplastic Stem Cells; Opportunistic Infections; Prostatectomy; Prostatic Neoplasms; Vorinostat | 2014 |
Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction | 2015 |
Minimal residual disease-directed therapy in acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein | 2015 |
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Doxorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Randomized Controlled Trials as Topic | 2015 |
[Klinefelter syndrome and acute myeloblastic leukaemia].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 8; Cytarabine; Cytogenetics; Genetic Predisposition to Disease; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Karyotyping; Klinefelter Syndrome; Leukemia, Myeloid, Acute; Male; Trisomy | 2009 |
Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Time Factors; Young Adult | 2009 |
[Standard therapies for acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Remission Induction | 2009 |
[Acute myeloid leukemia trials by Japan Adult Leukemia Study Group (JALSG)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Evidence-Based Medicine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Young Adult | 2009 |
Granulocytic sarcoma of abdomen in acute myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: case report and review of literature.
Topics: Abdominal Neoplasms; Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 6; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction; Sarcoma, Myeloid; Translocation, Genetic | 2010 |
[Acute myelogenous leukemia developed at the 26th week of gestation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Cytarabine; Female; Humans; Idarubicin; Infant, Low Birth Weight; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, Second; Remission Induction | 2011 |
Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Endometrial Neoplasms; Female; Gene Rearrangement; Genes, abl; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Soft Tissue Neoplasms; Submandibular Gland Neoplasms; Translocation, Genetic | 2012 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
Relapse of acute myeloid leukemia at the pituitary gland: a case report and review of literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Diabetes Insipidus; Etoposide; Female; Humans; Hypopituitarism; Idarubicin; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Methotrexate; Pituitary Neoplasms; Radiotherapy; Recurrence; Remission Induction; Vision Disorders | 2012 |
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gastrointestinal Tract; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Cytarabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Idarubicin; Leukemia, Myeloid, Acute; Vorinostat | 2012 |
Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.
Topics: Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 2013 |
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; France; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2003 |
Acute myelogenous leukemia in an adult with thrombocytopenia with absent radii syndrome.
Topics: Abnormalities, Multiple; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Cytokines; Female; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Menorrhagia; Neoplasm Proteins; Platelet Count; Proto-Oncogene Proteins; Radius; Receptors, Cytokine; Receptors, Thrombopoietin; Recurrence; Remission Induction; Risk; Syndrome; Thrombocytopenia | 2003 |
Acute myeloblastic leukemia in pregnancy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third | 2004 |
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2004 |
Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Remission Induction | 2007 |
Long-term propylthiouracil use and acute myeloid leukemia: a case report and review of the literature.
Topics: Adult; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 21; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Iodide Peroxidase; Leukemia, Myeloid, Acute; Peroxidase; Propylthiouracil; Remission Induction; Time Factors; Translocation, Genetic; Transplantation, Homologous | 2008 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
A review of idarubicin in acute leukemia.
Topics: Adult; Aged; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Daunorubicin; Europe; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 1993 |
[New anthracyclines].
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Carubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Experimental; Leukemia, Myeloid, Acute; Menogaril; Stomach Neoplasms | 1993 |
Primary extramedullary leukemia of the prostate: case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Diagnostic Errors; Doxorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prostatectomy; Prostatic Neoplasms; Radioisotope Teletherapy; Remission Induction; Urinary Retention; Vincristine | 1996 |
[Current situation and perspective for treatment of acute myelogenous leukemia in adults].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Remission Induction; Survival Rate; Tretinoin | 1998 |
Idarubicin including regimens in acute myelogenous leukemia in elderly patients.
Topics: Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pilot Projects; Randomized Controlled Trials as Topic | 1999 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
[Acute myelogenous leukemia associated with severe esophageal stricture after chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Esophageal Stenosis; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2002 |
Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Time Factors; Vincristine | 1992 |
Idarubicin: an anthracycline antineoplastic agent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Cytarabine; Drug Labeling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1992 |
New drugs in acute myelogenous leukemia: a review.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Isomerism; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction; Survival Rate; Tretinoin | 1992 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
Topics: Animals; Cells, Cultured; Daunorubicin; Humans; Idarubicin; Leukemia; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice | 1989 |
Treatment of relapsed and refractory acute myeloid leukemia in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction | 1989 |
159 trial(s) available for idarubicin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2022 |
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Remission Induction; Vidarabine | 2022 |
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine | 2022 |
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Idarubicin; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Valproic Acid | 2022 |
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Finland; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Prospective Studies; Remission Induction; Thioguanine | 2022 |
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Vidarabine | 2022 |
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Transplantation Conditioning | 2023 |
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Topics: Adult; Consolidation Chemotherapy; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors | 2023 |
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
Topics: Aged; Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2023 |
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Sorafenib | 2023 |
Gemtuzumab Ozogamicin in
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Progression-Free Survival; Prospective Studies; Tretinoin; Young Adult | 2020 |
Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.
Topics: Aged; Allografts; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Risk Factors | 2020 |
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Recurrence; Salvage Therapy; Triazoles | 2020 |
Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Retrospective Studies; Survival Rate; Vidarabine; Vincristine | 2021 |
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Triazoles; Vidarabine | 2021 |
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult | 2021 |
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult | 2017 |
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cohort Studies; Combined Modality Therapy; Cytarabine; Cytogenetic Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pravastatin; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction | 2018 |
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Nucleophosmin; Prospective Studies; Young Adult | 2019 |
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2019 |
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Retrospective Studies; Sorafenib; Survival Rate; Tandem Repeat Sequences | 2019 |
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Topics: Adolescent; Antibiotics, Antineoplastic; Bone Marrow; Child; Child, Preschool; Daunorubicin; Dose-Response Relationship, Drug; Female; Heart Diseases; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liposomes; Male; Multivariate Analysis; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Risk Factors; Treatment Outcome | 2013 |
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Drug Eruptions; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Nausea; Pilot Projects; Remission Induction; Survival Analysis; Young Adult | 2013 |
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Vidarabine; Young Adult | 2013 |
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Survival Rate | 2013 |
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2014 |
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Treatment Failure; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome | 2014 |
Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Female; Hospitalization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Outpatients; Treatment Outcome | 2014 |
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Critical Care; Cytarabine; Disease-Free Survival; Drug Synergism; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Survival Rate; Tretinoin; Valproic Acid | 2014 |
High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: promising post-remission therapy for acute myeloid leukemia in first complete remission?
Topics: Adolescent; Adult; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Rabbits; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2014 |
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Fibroblast Growth Factor 7; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Stomatitis | 2014 |
[Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Mitoxantrone; Russia | 2014 |
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pravastatin; Risk Factors; Survival Rate | 2015 |
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Databases, Factual; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Assessment; Survival Rate; United Kingdom | 2015 |
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 2016 |
Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Prognosis; Survival Rate | 2015 |
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Idarubicin; Indoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Neoplasm, Residual; Panobinostat; Prognosis; Recurrence; Treatment Outcome | 2015 |
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
Topics: Adolescent; Adult; Aged; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate | 2015 |
Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Biomarkers; Chromosome Aberrations; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Topoisomerase II Inhibitors; Treatment Outcome; Young Adult | 2016 |
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 2016 |
[Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction | 2016 |
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Cytarabine; Female; Humans; Idarubicin; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome | 2017 |
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Remission Induction | 2008 |
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Vidarabine; Young Adult | 2008 |
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid; Survival Rate; Treatment Outcome | 2008 |
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Salvage Therapy | 2008 |
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Vidarabine | 2008 |
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Cyclosporine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Idarubicin; Inhibitory Concentration 50; K562 Cells; Leukemia, Myeloid, Acute; Male; Rhodamine 123; Time Factors; Treatment Outcome; Verapamil | 2009 |
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Tretinoin; Vidarabine | 2009 |
Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
[Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2009 |
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2009 |
Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2009 |
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Vidarabine; Young Adult | 2009 |
[FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2009 |
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Interleukin-2; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Recurrence; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Precision Medicine; Prognosis; Remission Induction; Treatment Outcome; Young Adult | 2010 |
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Confidence Intervals; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Probability; Proportional Hazards Models; Radiotherapy, Adjuvant; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2010 |
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
Topics: Acetylation; Acute Disease; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase Inhibitor p21; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Histones; Humans; Hydroxamic Acids; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Poly-ADP-Ribose Binding Proteins; Recurrence; RNA, Messenger; Vorinostat; Young Adult | 2010 |
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Daunorubicin; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cohort Studies; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Treatment Outcome | 2011 |
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Analysis; Young Adult | 2011 |
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Female; Gene Expression; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Progenitor Cells; Oligonucleotides; Recurrence; RNA, Messenger; X-Linked Inhibitor of Apoptosis Protein | 2011 |
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Neoplasm Staging; Quinolones; Remission Induction; Risk; Young Adult | 2011 |
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Down-Regulation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; STAT3 Transcription Factor | 2011 |
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Sialic Acid Binding Ig-like Lectin 3 | 2011 |
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genes, p53; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Treatment Failure | 2012 |
[Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Young Adult | 2011 |
Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cytarabine; Female; Half-Life; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Young Adult | 2012 |
Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Child; Diazepam; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Young Adult | 2012 |
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Vorinostat | 2012 |
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gastrointestinal Tract; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Survival Rate; Time Factors; Vidarabine | 2013 |
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Topics: Aged; Aged, 80 and over; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Proportional Hazards Models; Time; Treatment Outcome | 2013 |
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Female; Humans; Idarubicin; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Survivin; Treatment Outcome | 2013 |
Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Bone Marrow Transplantation; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; New Zealand; Recurrence; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Tretinoin | 2003 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2003 |
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis | 2003 |
Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Child; Cytarabine; Etoposide; fas Receptor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytes, Mononuclear; Lymphocyte Depletion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Treatment Outcome | 2003 |
[Efficacy of idarubicin in the treatment of childhood acute non-lymphoblastic leukemia: report of Polish Pediatric Leukemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute | 2003 |
Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Patient Selection; Recurrence; Statistics, Nonparametric; Survival Rate; Thioguanine; Time Factors | 2004 |
Risk-adapted induction and consolidation therapy in adults with de novo AML aged
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis | 2004 |
Cytoprotection in acute myelogenous leukemia (AML) therapy.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytoprotection; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis | 2004 |
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine | 2005 |
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Interleukin-11; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Analysis | 2005 |
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Survival Rate; Treatment Outcome | 2005 |
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Remission Induction; Survival Rate; Transplantation, Homologous | 2005 |
Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients.
Topics: Adult; Cyclic N-Oxides; Doxorubicin; Drug Interactions; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Erythrocytes; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipid Bilayers; Membrane Fluidity; Membrane Proteins; Middle Aged; Viscosity | 2006 |
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult L
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Probability; Remission Induction; Risk Assessment; Treatment Outcome; Vincristine; Vindesine | 2005 |
[Multi-institutional randomized controlled clinical trial on China made 4-demethoxydaunokrubicin (IDA) in the treatment of acute leukemia].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; China; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Single-Blind Method | 2005 |
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Time Factors | 2006 |
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cytarabine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Safety | 2007 |
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucositis; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 2006 |
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Humans; Idarubicin; Infant; Infant, Newborn; Interleukin-2; Leukemia, Myeloid, Acute; Male; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Retrospective Studies; Time Factors | 2007 |
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Cytarabine; Female; Gene Expression Profiling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Pyrazines; Tissue Distribution; Treatment Outcome | 2008 |
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatmen
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Europe; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pilot Projects; Prognosis; Prospective Studies; Survival Analysis | 1995 |
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1993 |
[Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1994 |
Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Survival Analysis | 1994 |
[A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1993 |
Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Rate | 1993 |
Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Analysis | 1993 |
[New anthracyclines].
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Carubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Experimental; Leukemia, Myeloid, Acute; Menogaril; Stomach Neoplasms | 1993 |
[Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
Topics: Adult; Aged; Alopecia; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vomiting | 1993 |
[Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1993 |
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neutropenia; Pilot Projects; Remission Induction; Survival Rate | 1996 |
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Rate | 1996 |
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous | 1996 |
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group.
Topics: Aged; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 1996 |
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 1996 |
A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Topics: Adolescent; Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Data Interpretation, Statistical; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1996 |
Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Taiwan | 1996 |
Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction | 1996 |
Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Prospective Studies; Remission Induction | 1997 |
Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Prospective Studies | 1997 |
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Topics: Adolescent; Adult; Aged; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Time Factors | 1997 |
Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Area Under Curve; Chromatography, Liquid; Cross-Over Studies; Daunorubicin; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Spectrometry, Fluorescence | 1997 |
Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Agranulocytosis; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Nausea; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Chemotherapy, Adjuvant; Creatinine; Cyclosporine; Cytarabine; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome | 1998 |
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 1998 |
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Analysis; Vidarabine | 1999 |
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Danazol; Drug Screening Assays, Antitumor; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Analysis; Tamoxifen; Vidarabine | 1999 |
Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Rate | 1999 |
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Treatment Outcome | 2001 |
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Risk Factors; Survival Rate | 2001 |
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2001 |
Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Platelet Count; Survival Rate | 2001 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Platelets; Cell Count; Cytarabine; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Middle Aged; Thrombopoietin; Time Factors | 2002 |
Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Drug Administration Schedule; Feasibility Studies; Humans; Idarubicin; Infusions, Intravenous; Italy; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Thioguanine | 1992 |
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 1992 |
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocytosis; Male; Middle Aged; Remission Induction | 1992 |
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 1991 |
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Probability | 1991 |
Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
Topics: Administration, Oral; Aged; Biological Availability; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic | 1990 |
Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Remission Induction | 1989 |
Idarubicin in acute leukemia: results of US trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute | 1989 |
Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Random Allocation; Remission Induction | 1989 |
A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction | 1989 |
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
336 other study(ies) available for idarubicin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Co-Treatments of Edible Curcumin from Turmeric Rhizomes and Chemotherapeutic Drugs on Cytotoxicity and FLT3 Protein Expression in Leukemic Stem Cells.
Topics: Antigens, Neoplasm; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcuma; Curcumin; Cytoskeletal Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Rhizome | 2021 |
Ultraviolet recall due to cytarabine chemotherapy for acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2021 |
PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF-кB pathway activity and DNA damage response induced by Idarubicin
Topics: Cell Line, Tumor; DNA Damage; Humans; Idarubicin; Leukemia, Myeloid, Acute; NF-kappa B; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Sulfonamides; Vidarabine; Young Adult | 2022 |
Granulocytic sarcoma of cervix: A rare case report.
Topics: Cervix Uteri; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Sarcoma, Myeloid | 2022 |
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2022 |
Pneumocystis jirovecii pneumonia [PJP]: An unrecognized concern in AML patients on Venetoclax.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pneumocystis carinii; Pneumonia, Pneumocystis; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
[A comparative clinical study of modified IA "3+4" regimen and intermediate-dose cytarabine regimen in the consolidation treatment of low-risk acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2022 |
Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridge Therapy; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2023 |
Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2023 |
Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis.
Topics: Anti-Bacterial Agents; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2023 |
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Staurosporine | 2023 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Forkhead Transcription Factors; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; RNA, Messenger; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2023 |
[Acute myeloid leukemia with t (8;21) translocation diagnosed at 21 weeks of gestation resulting in full-term delivery without chemotherapy].
Topics: Adult; Cesarean Section; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pregnancy; Translocation, Genetic | 2023 |
Non-allogeneic immunotherapy in acute myeloid leukaemia.
Topics: Cytarabine; Humans; Idarubicin; Immunotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nivolumab | 2019 |
PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.
Topics: Cell Line, Tumor; Cytarabine; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Oxidative Phosphorylation; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction | 2019 |
Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Eruptions; Female; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes | 2020 |
A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.
Topics: Aclarubicin; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2020 |
The Role of Anthracyclines in Acute Myeloid Leukemia Consolidation.
Topics: Adolescent; Adult; Aged; Anthracyclines; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Young Adult | 2020 |
Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Topics: Adolescent; Adult; Aged; Alleles; Allografts; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Progression-Free Survival; Recurrence; Risk Assessment; Young Adult | 2020 |
Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Survival Rate; Vidarabine | 2020 |
Venetoclax for paediatric acute myeloid leukaemia: a step forward.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Child; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Feasibility Studies; Female; Gemtuzumab; Geriatric Assessment; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Outcome Assessment, Health Care; Survival Analysis | 2020 |
Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy.
Topics: Adult; Anti-Bacterial Agents; Bone Marrow; Consolidation Chemotherapy; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Linezolid; Male; Middle Aged; Platelet Count; Retrospective Studies; Thrombocytopenia | 2020 |
Diffuse alveolar hemorrhage during induction therapy for acute myeloid leukemia with inv(16)(p13.1q22).
Topics: Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Diagnosis, Differential; Hemorrhage; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Lung Diseases; Male; Middle Aged; Pulmonary Alveoli; Tomography, X-Ray Computed | 2020 |
FLAG-Ida is back in.
Topics: Anthracyclines; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2020 |
Immunosuppressive role of CD11b
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD11b Antigen; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytarabine; Cytotoxicity, Immunologic; Female; Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Phenotype; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes, Cytotoxic; Treatment Outcome; Tumor Escape | 2020 |
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia.
Topics: Adolescent; Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Cytarabine; Databases, Factual; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 2021 |
Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Rate; Young Adult | 2020 |
Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response.
Topics: Animals; Diterpenes; DNA Damage; DNA Repair; Drug Synergism; Epoxy Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Phenanthrenes | 2021 |
Diagnosis of oesophageal mucormycosis managed with medical therapy alone.
Topics: Amphotericin B; Antifungal Agents; Cytarabine; Esophageal Diseases; Esophagus; Humans; Idarubicin; Immunocompromised Host; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucormycosis; Rhizopus; Triazoles | 2020 |
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Prospective Studies; Receptors, Immunologic; Survival Rate; Young Adult | 2021 |
A novel dipeptide type inhibitor of the Wnt/β-catenin pathway suppresses proliferation of acute myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dipeptides; Drug Design; Drug Evaluation, Preclinical; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Luciferases; Wnt Signaling Pathway | 2021 |
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |
Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pancytopenia; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult | 2021 |
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Vidarabine | 2021 |
Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2022 |
Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia with t(8;21).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Diagnosis, Differential; Eosinophilia; Eosinophils; Exanthema; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Skin; Translocation, Genetic; Treatment Outcome; Young Adult | 2017 |
Cell-based evaluation of changes in coagulation activity induced by antineoplastic drugs for the treatment of acute myeloid leukemia.
Topics: Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cytarabine; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Phosphatidylserines; Tetrahydronaphthalenes; Thrombomodulin; Thromboplastin | 2017 |
Escalated anthracycline dose in adult AML.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
A life-threatening ruxolitinib discontinuation syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Janus Kinase 2; Leukemia, Myeloid, Acute; Middle Aged; Nitriles; Pneumonia; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Remission Induction; Respiratory Distress Syndrome; Substance Withdrawal Syndrome; Thrombocythemia, Essential; Tomography, X-Ray Computed | 2017 |
Release of Danger-Associated Molecular Patterns following Chemotherapy Does Not Induce Immunoparalysis in Leukemia Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers; Case-Control Studies; Cells, Cultured; Cholesterol, LDL; Cytarabine; Cytokines; DNA; DNA, Mitochondrial; Female; HLA-DR Antigens; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Leukocytes; Lipopolysaccharides; Male; Middle Aged; Myelodysplastic Syndromes; Young Adult | 2017 |
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; DNA Damage; DNA Repair; Drug Therapy; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Young Adult | 2017 |
Systemic mastocytosis associated with acute myeloid leukaemia.
Topics: Adult; Biopsy, Needle; Bone Marrow; Cytarabine; Humans; Idarubicin; Immunohistochemistry; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit | 2017 |
Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Binding Factor; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Myosin Heavy Chains; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Reverse Transcriptase Polymerase Chain Reaction; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Transplantation, Autologous | 2017 |
FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Analysis; Vascularized Composite Allotransplantation; Vidarabine | 2017 |
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine | 2017 |
Anthracycline-induced acute myocarditis and ventricular fibrillation arrest.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cardiopulmonary Resuscitation; Chest Pain; Combined Modality Therapy; Cytarabine; Defibrillators, Implantable; Echocardiography; Etoposide; Heart Arrest; Humans; Idarubicin; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Middle Aged; Myocarditis; Ventricular Fibrillation | 2018 |
Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Propensity Score; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Vidarabine | 2019 |
Ara-C ears: an actual drug-induced reaction or a distinctive manifestation of a neutrophilic dermatosis?
Topics: Adult; Biopsy; Cytarabine; Drug Therapy, Combination; Ear Diseases; Ear, External; Erythema; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Sweet Syndrome | 2018 |
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genes, p53; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2018 |
High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Remission Induction; Salvage Therapy; Survival Analysis; United Kingdom; Vidarabine | 2018 |
Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Acute Onset Unilateral Proptosis.
Topics: Aged; Antineoplastic Agents; Cytarabine; Exophthalmos; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Radiotherapy; Sarcoma, Myeloid | 2018 |
[Complete Remission Rate and Adverse Ractions of Three Different Chemotherapy Regimens in the Treatment of Adult Patients with Newly Diagnosed Non-M3 AML].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2018 |
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine | 2018 |
Cardiac arrest in a patient diagnosed with acute myeloid leukemia after the first dose of idarubicin.
Topics: Antibiotics, Antineoplastic; Heart Arrest; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 2018 |
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; United Kingdom; Vidarabine; Young Adult | 2018 |
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine | 2019 |
Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.
Topics: Cell Line, Tumor; Cell Survival; Cytarabine; DNA; DNA Adducts; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mass Spectrometry | 2018 |
FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Lomustine in older patients with acute myeloid leukaemia.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2018 |
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Monitoring; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Precision Medicine; Prognosis; Remission Induction; ROC Curve; Treatment Outcome; Workflow; Young Adult | 2019 |
FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Vidarabine | 2019 |
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Europe; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Platelet Count; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Rate; Young Adult | 2019 |
Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Time Factors | 2019 |
Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Russia; Survival Rate; Young Adult | 2018 |
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 2019 |
Clinical Reasoning: A pregnant woman with chin numbness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chin; Consolidation Chemotherapy; Cytarabine; Emergency Service, Hospital; Fatigue; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypesthesia; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Paresthesia; Pregnancy; Pregnancy Complications, Neoplastic; Spinal Puncture; Sweating; Upper Extremity | 2019 |
Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Young Adult | 2019 |
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; Disease-Free Survival; DNA Methylation; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Time Factors | 2019 |
Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Cytarabine; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction | 2019 |
First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia.
Topics: Antibiotics, Antineoplastic; Cardiomyopathies; Fatal Outcome; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute | 2019 |
FLAI induction regimen in elderly patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Sex Factors; Time Factors; Transplantation, Homologous; Vidarabine | 2019 |
Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Cell Proliferation; DNA Repair; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Gossypol; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Prognosis; RUNX1 Translocation Partner 1 Protein; Survival Rate; Synthetic Lethal Mutations; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Young Adult | 2019 |
Core binding factor acute myeloid leukaemia and c-KIT mutations.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Core Binding Factors; Cytarabine; Disease-Free Survival; Etoposide; Exons; Female; Humans; Idarubicin; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-kit; Retrospective Studies; Stem Cell Transplantation; Young Adult | 2013 |
Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology.
Topics: Anthracyclines; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Societies, Scientific; Tretinoin; United States | 2013 |
[Analysis on clinical response of IA and DA regimens in the treatment of 74 newly diagnosed acute myeloid leukemia patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2013 |
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine | 2013 |
Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Topics: 5'-Nucleotidase; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine Kinase; DNA Methylation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Inactivation, Metabolic; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Nucleophosmin; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Survival Analysis; Tandem Repeat Sequences; Topoisomerase I Inhibitors; Young Adult | 2013 |
Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Arterial Occlusive Diseases; Bone Marrow Examination; Combined Modality Therapy; Cyanosis; Cytarabine; Diagnosis, Differential; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Humans; Idarubicin; Ischemia; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Shoes; Thrombectomy; Thrombocytopenia; Thrombosis; Toes; Ultrasonography | 2013 |
The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.
Topics: Aged; Aged, 80 and over; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Risk; Severity of Illness Index; Treatment Outcome | 2013 |
Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prevalence; Prognosis; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Fungal; Fatal Outcome; Female; Fever; Fusariosis; Fusarium; Humans; Idarubicin; Leukemia, Myeloid, Acute; Triazoles; Young Adult | 2014 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors.
Topics: Apoptosis; Blotting, Western; Cell Cycle; Cell Line; Cell Survival; Diterpenes; Epoxy Compounds; Flow Cytometry; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; NF-E2-Related Factor 2; Phenanthrenes; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction | 2013 |
The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Immunophenotyping; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2014 |
Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Dexamethasone; Erythroid Cells; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Megakaryocytes; Mitoxantrone; Neoplasms, Second Primary; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vincristine | 2014 |
Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factors; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Translocation, Genetic; Treatment Outcome; Young Adult | 2014 |
HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Graft Survival; Graft vs Leukemia Effect; Histocompatibility; HLA Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Male; Middle Aged; Remission Induction; Tissue Donors | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
The first Korean case of Moraxella osloensis bacteremia in a patient with acute myeloid leukemia.
Topics: Aged; Ampicillin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Asian People; Cytarabine; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Moraxella; Moraxellaceae Infections; Republic of Korea; Respiratory Tract Infections; RNA, Ribosomal, 16S; Sequence Analysis, RNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulbactam | 2014 |
Acute basophilic leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antigens, CD; Antimetabolites, Antineoplastic; Asthenia; Azacitidine; Basophils; Bone Marrow; Cytarabine; Female; Humans; Idarubicin; Leukemia, Basophilic, Acute; Leukemia, Myeloid, Acute | 2014 |
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Child; Child, Preschool; Cytarabine; Etoposide; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2014 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
[Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mast Cells; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Vidarabine | 2015 |
Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2015 |
[Clinical curative efficacy of inducing remission for the newly diagnosed aged AML patients by chemotherapy with IA and DA regimens].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 2014 |
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Monitoring; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Survival Analysis; Transcription Factors; Translocation, Genetic | 2015 |
Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Female; Follow-Up Studies; Hospitalization; Humans; Idarubicin; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
A "body armor" of leukemia cutis.
Topics: Adult; Antineoplastic Agents; Cell Movement; Daunorubicin; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Sarcoma, Myeloid; Skin; Skin Neoplasms; Transplantation, Homologous | 2015 |
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Survival Analysis; Treatment Outcome; Vidarabine | 2015 |
[The relationship between induction chemotherapy cycles and prognosis in patients with acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Prognosis; Remission Induction | 2015 |
"Cup-like" blasts in acute myeloid leukemia with FLT3 and NPM1 mutations.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin | 2015 |
[Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Prognosis; Remission Induction | 2015 |
Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Case-Control Studies; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Endostatins; Female; Fibroblast Growth Factors; Gene Expression; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; ROC Curve; Treatment Outcome | 2015 |
Successful Treatment With Total Skin Electron Beam Therapy in a Child With Isolated Cutaneous Relapsed AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Electrons; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Skin Diseases; Vidarabine | 2015 |
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Genome, Human; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mutation; Outcome Assessment, Health Care; Polymorphism, Genetic; Prognosis; Recurrence; RNA, Messenger; Sequence Analysis, RNA | 2015 |
Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Proliferation; Cytarabine; Drug Delivery Systems; Enzyme Activation; Female; Fingolimod Hydrochloride; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipids; Mice; Mice, Transgenic; Nanoparticles; Nanotechnology; Propylene Glycols; Sphingosine | 2015 |
Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Cytogenetic Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Thioguanine; Young Adult | 2015 |
The impact of standard chemotherapy on miRNA signature in plasma in AML patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mitoxantrone; Pilot Projects; Real-Time Polymerase Chain Reaction; Remission Induction; RNA, Neoplasm; Transcriptome | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome; Young Adult | 2015 |
Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Synergism; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2015 |
The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; China; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Gene Frequency; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-kit; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Topics: Cytarabine; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Wernicke's Encephalopathy in an Acute Myeloid Leukemia Patient: A Case Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Thiamine; Vidarabine; Wernicke Encephalopathy | 2016 |
Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Guideline Adherence; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Practice Guidelines as Topic | 2016 |
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Consolidation Chemotherapy; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2016 |
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Vidarabine; Young Adult | 2016 |
Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cytarabine; Daunorubicin; Echinocandins; Febrile Neutropenia; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipopeptides; Male; Micafungin; Middle Aged; Mycoses; Prospective Studies; Young Adult | 2016 |
Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2016 |
Genomic and transcriptomic profiles and in vitro resistance to mitoxantrone and idarubicin in pediatric acute leukemias.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Child; Cluster Analysis; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2016 |
[A Case of a Multidisciplinary Team Approach to Serious Hand-Foot Syndrome Induced by High-Dose Cytarabine Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Erythema; Female; Hand-Foot Syndrome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Patient Care Team; Treatment Outcome | 2016 |
The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies | 2016 |
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Topics: Adult; Aged; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction | 2017 |
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Safety; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Gene Silencing; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Mice; Mice, SCID; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Microenvironment | 2017 |
Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Thioguanine; Tumor Suppressor Protein p53 | 2017 |
Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Tretinoin | 2016 |
Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.
Topics: Amino Acid Motifs; Base Sequence; Cytarabine; fms-Like Tyrosine Kinase 3; Gene Expression; Genetic Variation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Protein Domains; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Tandem Repeat Sequences | 2017 |
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Stem Cell Transplantation; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Dosage; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Proto-Oncogene Proteins; Recurrence; Remission Induction; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2008 |
Neutrophilic dermatoses with acute myeloid leukemia associated with an increase of serum colony-stimulating factor.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Folliculitis; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sweet Syndrome | 2008 |
Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cytarabine; Down-Regulation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Ligands; Signal Transduction; Up-Regulation | 2009 |
[Loeys-Dietz syndrome with acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Marfan Syndrome; Middle Aged; Mutation, Missense; Receptors, Transforming Growth Factor beta; Remission Induction; Translocation, Genetic | 2008 |
The management of prolonged, isolated hyperbilirubinemia following cytarabine-based chemotherapy for acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 2009 |
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Cytogenetic Analysis; Daunorubicin; Decision Making; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Patient Selection; Practice Guidelines as Topic; Risk Factors; Survival Analysis | 2008 |
Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Diterpenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Epoxy Compounds; Humans; I-kappa B Proteins; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Phenanthrenes; X-Linked Inhibitor of Apoptosis Protein | 2008 |
Human leukocyte antigen-DR negative de novo acute myeloid leukemia with Philadelphia chromosome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Philadelphia Chromosome; Remission Induction | 2008 |
[Granulocytic sarcoma of the prostate presenting with urinary obstruction which progressed to acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Dysuria; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Remission Induction; Sarcoma, Myeloid | 2008 |
Life-threatening conjunctival presentation of myeloid sarcoma.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Conjunctival Neoplasms; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary; Sarcoma, Myeloid; Skin Neoplasms | 2008 |
Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : report on one case and review of other uses in acute leukemias.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Factor VIIa; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid, Acute; Recombinant Proteins; Remission Induction; Thrombocytopenia; Treatment Outcome | 2010 |
Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous | 2009 |
Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers; Case-Control Studies; Cytarabine; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies | 2009 |
DNA damage response as a biomarker in treatment of leukemias.
Topics: Adolescent; Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Cell Cycle Proteins; Child; Daunorubicin; DNA Damage; DNA Topoisomerases; DNA-Binding Proteins; Enzyme Inhibitors; Histones; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Topoisomerase Inhibitors; Tumor Suppressor Proteins | 2009 |
An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma.
Topics: Antineoplastic Agents; Cytarabine; Female; Humans; Idarubicin; Intestinal Obstruction; Intestine, Small; Leukemia, Myeloid, Acute; Middle Aged; Sarcoma, Myeloid; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Blast Crisis; Blotting, Western; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Young Adult | 2009 |
Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2009 |
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Apoptosis; Daunorubicin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Tumor Cells, Cultured; Young Adult | 2009 |
Successful treatment of Hodgkin lymphoma and acute leukemia.
Topics: Adult; Biopsy; Bone Marrow Cells; Cytarabine; Hodgkin Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Remission Induction | 2010 |
Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Republic of Korea; Retrospective Studies; Survival Analysis; Thioguanine; Young Adult | 2010 |
Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Injections, Spinal; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Male; Meninges; Middle Aged; Mitoxantrone; Testis; Young Adult | 2010 |
Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Digestive System Surgical Procedures; Enterococcus faecium; Fatal Outcome; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mucormycosis; Neutropenia; Rhinitis; Shock, Septic; Sinusitis; Typhlitis | 2010 |
Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Female; Genes, Wilms Tumor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Survival Rate; Time Factors; Transcription, Genetic; Treatment Outcome; WT1 Proteins; Young Adult | 2010 |
Brucellosis: a rare cause of febrile neutropenia in acute myeloblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brucellosis; Cytarabine; Diagnosis, Differential; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neutropenia; Prognosis; Remission Induction | 2011 |
Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Prognosis; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Young Adult | 2010 |
Toxic shock syndrome caused by hospital-acquired methicillin-resistant Staphylococcus aureus in a patient with pancytopenia.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cross Infection; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Methicillin-Resistant Staphylococcus aureus; Multiple Organ Failure; Pancytopenia; Shock, Septic; Staphylococcal Infections | 2010 |
The development of congestive heart failure and ventricular tachycardia after first exposure to idarubicin in a patient with acute myeloid leukaemia.
Topics: Adult; Antibiotics, Antineoplastic; Female; Heart Failure; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tachycardia, Ventricular | 2010 |
Orbital mass as a presenting sign of acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Fatal Outcome; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Orbital Neoplasms | 2010 |
Central line-associated bacteremia caused by drug-resistant Staphylococcus caprae after chemotherapy for acute myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Staphylococcus | 2010 |
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Leukemia cutis limited to the needle puncture sites.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cytarabine; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Skin Neoplasms | 2010 |
Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacteria; Blood; Cytarabine; Female; Finland; Humans; Idarubicin; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Prospective Studies; Sepsis; Thioguanine; Young Adult | 2010 |
Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Trisomy; Young Adult | 2010 |
Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Systemic mastocytosis associated with acute myeloid leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Cells; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mast Cells; Mastocytosis, Systemic | 2010 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cytarabine; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia?
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lomustine; Nitrosourea Compounds; Treatment Outcome | 2010 |
Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Administration Schedule; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Finland; Granulocyte Colony-Stimulating Factor; Humans; Iceland; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Remission Induction; Risk Assessment; Scandinavian and Nordic Countries; Survival Analysis | 2011 |
Acquired protein C deficiency in a child with acute myelogenous leukemia, splenic, renal, and intestinal infarction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cholecystectomy; Cytarabine; Etoposide; Fibrin Fibrinogen Degradation Products; Fibrinogen; Gallbladder; Heparin, Low-Molecular-Weight; Humans; Idarubicin; Infarction; Kidney; Lebanon; Leukemia, Myeloid, Acute; Male; Protein C; Protein C Deficiency; Remission Induction; Splenectomy; Splenic Infarction; Thrombosis; Tretinoin | 2011 |
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Binding, Competitive; Clinical Trials, Phase II as Topic; Cytarabine; Drug Synergism; Eukaryotic Initiation Factor-4E; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Ribavirin; RNA Caps; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2011 |
Smoking adversely affects survival in acute myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Smoking; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Utility of myeloperoxidase stain in the differential diagnosis of leukemia cutis vs. hystiocitoid Sweet syndrome.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Diagnosis, Differential; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Peroxidase; Skin; Skin Neoplasms; Staining and Labeling; Sweet Syndrome; Treatment Outcome | 2011 |
Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Pancytopenia; Pyoderma Gangrenosum; Wound Healing | 2011 |
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
Prompt and definitive diagnosis of acute invasive Aspergillus rhinosinusitis in a patient with acute myeloid leukaemia using in situ hybridization: a case report.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillus; Cytarabine; Humans; Idarubicin; In Situ Hybridization; Itraconazole; Leukemia, Myeloid, Acute; Male; Mycological Typing Techniques; Rhinitis; Sinusitis | 2012 |
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Remission Induction; Sorafenib; Survival Rate | 2011 |
Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cytogenetic Analysis; Etoposide; Female; Hospitals, University; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Palliative Care; Prognosis; Retrospective Studies; Thioguanine; Treatment Outcome | 2011 |
Is obesity a prognostic factor for acute myeloid leukemia outcome?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Clinical Trials, Phase I as Topic; Cytarabine; Databases, Factual; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Obesity; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Treatment Outcome; Vidarabine | 2012 |
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Nucleophosmin; Polymorphism, Single Nucleotide; Prognosis | 2012 |
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
Topics: Adolescent; Adult; Aged; Animals; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mice; Mice, SCID; Middle Aged; Mutation; Nucleophosmin; Prognosis; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult | 2011 |
Myeloperoxidase expression in acute myeloid leukemia helps identifying patients to benefit from transplant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Peroxidase; Retrospective Studies; Young Adult | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Enzymes; Female; Gemtuzumab; Genetic Heterogeneity; Genotype; Humans; Idarubicin; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine | 2013 |
Copy number variations in normal karyotype acute myeloid leukaemia and their association with treatment response.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Copy Number Variations; Drug Resistance, Neoplasm; Female; Genome-Wide Association Study; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Prognosis; Republic of Korea; Survival Analysis; Young Adult | 2012 |
Acute myeloid leukaemia with abnormal eosinophil precursors without inversion 16.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Eosinophilia; Eosinophils; Granulocyte Precursor Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oncogene Proteins, Fusion | 2012 |
Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis | 2012 |
[Genetic prognostic factors in childhood acute myeloid leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Cytarabine; DNA Mutational Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Genetic Markers; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Translocation, Genetic | 2012 |
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Core Binding Factors; Cytarabine; Disease-Free Survival; Exons; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Korea; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Point Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; RUNX1 Translocation Partner 1 Protein; Transcription Factors; Translocation, Genetic; Treatment Outcome; Young Adult | 2013 |
Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Young Adult | 2013 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
Outcome of poor response paediatric AML using early SCT.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Early Medical Intervention; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloablative Agonists; Thioguanine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2013 |
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; RNA, Messenger | 2013 |
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Time-to-Treatment; Treatment Outcome; Young Adult | 2013 |
The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Topics: Adolescent; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Child, Preschool; Daunorubicin; Flow Cytometry; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tetrazolium Salts; Thiazoles | 2002 |
Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colitis; Cytarabine; Female; Humans; Idarubicin; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Retrospective Studies; Treatment Outcome | 2002 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
Enterocolitis as initial presentation of acute myelogenous leukemia exacerbated by induction chemotherapy with idarubicin-cytosine arabinoside.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colitis; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia | 2002 |
Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro.
Topics: Apoptosis; Cell Division; Cell Survival; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Hirudins; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Receptor, PAR-1; Thrombin; Time Factors | 2002 |
Acute myelogenous leukaemia presenting as a conjunctival lesion and red eye.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Conjunctiva; Conjunctival Neoplasms; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2002 |
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Recurrence | 2003 |
A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13).
Topics: Acetyltransferases; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 16; Cytarabine; Female; Gene Rearrangement; Histone Acetyltransferases; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Reverse Transcriptase Polymerase Chain Reaction; Saccharomyces cerevisiae Proteins; Sequence Analysis, DNA; Translocation, Genetic | 2003 |
Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacillaceae Infections; Bacillus cereus; Cytarabine; Enterocolitis; Fatal Outcome; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liver Diseases; Male; Neutropenia; Sepsis | 2003 |
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
Severe hyperglycemia as a complication of big ICE chemotherapy in a patient with acute myeloblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cytarabine; Etoposide; Female; Humans; Hyperglycemia; Idarubicin; Insulin; Leukemia, Myeloid, Acute; Recurrence; Time Factors | 2002 |
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Topics: Acute Disease; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Daunorubicin; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Risk Factors; Tandem Repeat Sequences | 2003 |
Sweet's syndrome masquerading as facial cellulitis.
Topics: Antineoplastic Agents; Cellulitis; Cytarabine; Diagnosis, Differential; Face; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Sweet Syndrome; Treatment Outcome | 2003 |
A case of leukemia of the appendix presenting as acute appendicitis.
Topics: Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendicitis; Appendix; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mercaptopurine; Sarcoma, Myeloid | 2003 |
[High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bradycardia; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2003 |
Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Cytogenetic Analysis; Daunorubicin; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Male; Prednisone; Retrospective Studies; Treatment Outcome; Vincristine | 2003 |
[Intensive multi-drug chemotherapy for acute myeloid leukemia in a renal allograft recipient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Kidney Transplantation; Leukemia, Myeloid, Acute; Male; Middle Aged; Postoperative Complications | 2003 |
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Salvage Therapy; Transplantation, Autologous | 2003 |
[Acute myelogenous leukemia complicated with severe tumor lysis syndrome after a single day of idarubicin/cytarabine chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Lysis Syndrome | 2003 |
Idarubicin administered during pregnancy: its effects on the fetus.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Drug Therapy, Combination; Female; Fetus; Gestational Age; Heart Rate, Fetal; Humans; Idarubicin; Leukemia, Myeloid, Acute; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Shock, Septic; Treatment Outcome | 2004 |
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chi-Square Distribution; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Logistic Models; Male; Mitoxantrone; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Survival Rate | 2004 |
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Ecthyma; Female; gamma-Globulins; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pseudomonas aeruginosa; Pseudomonas Infections; Scalp; Sepsis; Treatment Outcome | 2004 |
Complex t(8;14;21)(q22;q13;q22), a variant of t(8;21), with t(15;21)(q15;p11) in a patient with acute myelogenous leukemia (M1).
Topics: Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Therapy, Combination; Female; Genetic Variation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Middle Aged; Oncogene Proteins, Fusion; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Secondary Prevention; Transcription Factors; Translocation, Genetic | 2004 |
A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Tretinoin | 2004 |
Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Line, Tumor; Cell Survival; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Sialic Acid Binding Ig-like Lectin 3; Signal Transduction | 2005 |
Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA-Binding Proteins; Etoposide; GTPase-Activating Proteins; Histone-Lysine N-Methyltransferase; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Proto-Oncogenes; RNA, Messenger; Transcription Factors | 2005 |
Trying to improve clinical outcome in AML: lessons from negative trials.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Interleukin-11; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Antibiotics, Antineoplastic; Aorta; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Guinea Pigs; Heart Atria; Humans; Idarubicin; K562 Cells; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Organ Culture Techniques; Verapamil | 2006 |
Medical ethics collides with public policy: LVAD for a patient with leukemia.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cost-Benefit Analysis; Cytarabine; Health Care Rationing; Heart-Assist Devices; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Public Policy; United States | 2005 |
Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Methylprednisolone; Neutropenia; Recombinant Proteins; Recurrence; Sweet Syndrome; Vidarabine | 2006 |
Acute myeloid leukemia with near-triploid karyotype and extramedullary involvement of mediastinum.
Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Central Nervous System; Cytarabine; Disease Progression; Etoposide; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Mediastinum; Polyploidy; Prognosis; Stem Cell Transplantation; Tomography, X-Ray Computed | 2005 |
Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Caspofungin; Combined Modality Therapy; Cytarabine; Debridement; Diplopia; Drug Therapy, Combination; Echinocandins; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Lipopeptides; Male; Middle Aged; Mitoxantrone; Opportunistic Infections; Orbital Diseases; Peptides, Cyclic; Sinusitis; Zygomycosis | 2005 |
Neutrophilic eccrine hidradenitis masquerading as facial cellulitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cellulitis; Cytarabine; Diagnosis, Differential; Facial Dermatoses; Female; Follow-Up Studies; Hidradenitis; Humans; Idarubicin; Immunohistochemistry; Leukemia, Myeloid, Acute; Risk Assessment | 2007 |
Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leupeptins; Male; Membrane Proteins; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Cells, Cultured | 2007 |
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome; Vidarabine | 2007 |
Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2).
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Cytogenetic Analysis; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Nucleic Acid Hybridization; Oncogene Proteins, Fusion; Polymerase Chain Reaction; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic | 2008 |
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2007 |
Aberrant phenotype of plasmacytoid monocytes in acute myeloid leukemia.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Bone Marrow; Cell Differentiation; Clone Cells; Cytarabine; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Methotrexate; Middle Aged; Monocytes; Neoplasm Proteins; Neoplastic Stem Cells | 2008 |
Acute myeloid leukaemia presenting as recurrent generalized urticaria in infancy.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Diagnosis, Differential; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Urticaria | 2008 |
Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia.
Topics: Chromosomes, Human, Pair 3; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Philadelphia Chromosome; Syndrome; Time Factors | 2008 |
[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Evidence-Based Medicine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vincristine | 2007 |
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Topics: Adolescent; Adult; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Risk Factors; Survival Analysis; Treatment Outcome | 2008 |
Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia.
Topics: Aged; Allopurinol; Anti-Infective Agents; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Eruptions; Exanthema Subitum; Female; Fever; Hematopoiesis; Herpesvirus 6, Human; Histiocytosis; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Middle Aged; Skin; Virus Activation | 2008 |
Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Indomethacin; Leukemia, Myeloid, Acute; Multidrug Resistance-Associated Proteins; Phenotype | 2008 |
Two possible cases of Trichosporon infections in bone-marrow-transplanted children: the first case of T. japonicum isolated from clinical specimens.
Topics: Antibiotics, Antineoplastic; Antifungal Agents; Bone Marrow Transplantation; Child; Fatal Outcome; Female; Humans; Idarubicin; Immunocompromised Host; Infant; Itraconazole; Leukemia, Myeloid, Acute; Male; Mycoses; Neutropenia; Opportunistic Infections; Polymerase Chain Reaction; Trichosporon | 2008 |
[Acute myocardial infarction after cytostatic therapy].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Electrocardiography; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Myocardial Infarction | 1995 |
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Heart; Heart Failure; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Risk Factors; Stroke Volume | 1995 |
Aggressive chemotherapy for acute leukemia relapsed after transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Humans; Idarubicin; Italy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Tretinoin; Vincristine | 1994 |
Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
Topics: Acute Disease; Aged; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 1994 |
Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
Topics: Adolescent; Adult; Daunorubicin; Drug Resistance; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Tumor Cells, Cultured; Verapamil | 1994 |
[The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Hematopoiesis; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisolone; Remission Induction; Time Factors; Vincristine | 1993 |
Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Drug Administration Schedule; Drug Resistance; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1993 |
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cyclosporine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mathematical Computing; Monitoring, Physiologic; Probability; Remission Induction; Research Design | 1996 |
Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML).
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1995 |
Cutaneous eruption of lymphocyte recovery mimicking mycosis fungoides in a patient with acute myelocytic leukemia.
Topics: CD4 Antigens; Cytarabine; Diagnosis, Differential; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Mycosis Fungoides; Skin | 1995 |
Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Recurrence; Translocation, Genetic | 1996 |
Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo.
Topics: Antigens, CD34; Daunorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Leukemia, Myeloid, Acute; Morpholines; Rhodamine 123; Rhodamines; Triamterene | 1996 |
Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Daunorubicin; DNA Topoisomerases, Type II; Etoposide; Humans; Hydrogen-Ion Concentration; Idarubicin; Leukemia, Myeloid, Acute; Podophyllotoxin; Precipitin Tests; Topoisomerase II Inhibitors | 1996 |
Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blast Crisis; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Hydrogen-Ion Concentration; Idarubicin; Isoenzymes; Leukemia, Myeloid, Acute; Poly-ADP-Ribose Binding Proteins; Prognosis; Tumor Cells, Cultured | 1996 |
Marked bone marrow eosinophilia at the time of relapse of acute myeloblastic leukaemia in association with the appearance of translocation t(12;20)(q24;q11).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Eosinophilia; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Translocation, Genetic | 1996 |
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Central Nervous System Neoplasms; Chromosomes, Human, Pair 8; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Neoplasms; Trisomy; Vidarabine | 1995 |
Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.
Topics: Bone Marrow; Daunorubicin; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Humans; Idarubicin; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Topoisomerase II Inhibitors | 1997 |
Acute abdomen due to endometriosis as a diagnostic and therapeutic challenge in the treatment of acute myelocytic leukemia.
Topics: Abdomen, Acute; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Endometriosis; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged | 1997 |
Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
Topics: Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Fluorescent Dyes; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhodamines | 1997 |
Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Idarubicin; Immunosuppression Therapy; Kidney Transplantation; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Transplantation, Homologous | 1997 |
Idarubicin-induced pigmentary changes of the nails.
Topics: Adult; Antibiotics, Antineoplastic; Biopsy; Humans; Hyperpigmentation; Idarubicin; Leukemia, Myeloid, Acute; Male; Nail Diseases | 1997 |
Angioimmunoblastic lymphadenopathy with disseminated human herpesvirus 6 infection in a patient with acute myeloblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Cytarabine; DNA, Viral; Fatal Outcome; Fever; Herpesviridae Infections; Herpesvirus 6, Human; Humans; Hypergammaglobulinemia; Idarubicin; Immunoblastic Lymphadenopathy; Immunophenotyping; Leukemia, Myeloid, Acute; Lymph Nodes; Male; Middle Aged; Pericarditis; Polymerase Chain Reaction; Remission Induction; Tumor Virus Infections | 1997 |
Early transformation to acute myeloblastic leukaemia with the acquisition of inv(16) in Ph positive chronic granulocytic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Chromosome Inversion; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Humans; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Philadelphia Chromosome | 1997 |
[IL-2 post-autologous transplant of hematopoietic stem cells].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Chromatography, High Pressure Liquid; Daunorubicin; Half-Life; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged; Regression Analysis | 1997 |
Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Marrow Cells; Child, Preschool; Cytarabine; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Karyotyping; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Treatment Outcome | 1998 |
[Successful treatment with idarubicin in a pediatric case of t(8;21) acute myelogenous leukemia with additional chromosomal abnormalities at relapse].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Translocation, Genetic; Treatment Outcome | 1998 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Bacteremia caused by a novel isolate resembling leptotrichia species in a neutropenic patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cytarabine; Gram-Negative Anaerobic Straight, Curved, and Helical Rods; Gram-Negative Bacterial Infections; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Microscopy, Electron; Middle Aged; Neutropenia; Phylogeny | 1999 |
Acute myeloblastic leukemia (M0) with an unusual chromosomal abnormality: translocation (1;14)(p13;q32).
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 14; Cytarabine; Female; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Peroxidase; Translocation, Genetic | 1999 |
Acute myeloid leukemia M2 and t(8;21)(q22;q22) with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-), and CD33(-).
Topics: Adult; Antibiotics, Antineoplastic; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Bone Marrow Cells; CD13 Antigens; Cell Adhesion Molecules; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Lipopolysaccharide Receptors; Male; Membrane Glycoproteins; Peroxidase; Phenotype; Sialic Acid Binding Ig-like Lectin 3; Translocation, Genetic | 1999 |
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia.
Topics: Cyclosporine; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Idarubicin; Leukemia, Myeloid, Acute; Time Factors; Verapamil | 1999 |
Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.
Topics: Antibiotics, Antineoplastic; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow Cells; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Daunorubicin; Drug Resistance, Multiple; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Idarubicin; Idoxuridine; Leukemia, Myeloid, Acute; Verapamil | 1999 |
The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Idarubicin; Immunohistochemistry; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Survival Rate; Tretinoin; Vault Ribonucleoprotein Particles | 1999 |
MTT assay for drug resistance in childhood acute leukemia and effect of cyclosporin and interferon. A preliminary report.
Topics: Antineoplastic Agents; Bone Marrow; Cell Survival; Child; Cyclosporine; Drug Screening Assays, Antitumor; Humans; Idarubicin; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Recombinant Proteins; Tumor Cells, Cultured | 1999 |
Pulmonary infection caused by Gymnascella hyalinospora in a patient with acute myelogenous leukemia.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Ascomycota; Cytarabine; Drug Resistance, Microbial; Female; Humans; Idarubicin; Itraconazole; Leukemia, Myeloid, Acute; Lung Diseases, Fungal; Midwestern United States; Mycological Typing Techniques | 2000 |
In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Calcium Channel Blockers; Daunorubicin; Dihydropyridines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Verapamil | 2000 |
3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Drug Administration Schedule; Female; Germany; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Pilot Projects; Remission Induction; Treatment Outcome | 2000 |
[Two cases of acute myelogenous leukemia complicated with fatal gastrointestinal tract bleeding after treatment with idarubicin and cytarabine].
Topics: Adult; Antibiotics, Antineoplastic; Bone Marrow; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 2000 |
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 2000 |
Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liver Neoplasms; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Prednisolone; Remission Induction; Reoperation | 2000 |
[In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Myelodysplastic Syndromes; Tumor Cells, Cultured | 2000 |
Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate; T-Lymphocytes | 2000 |
Idarubicin oral: new formulation. No proven benefit over 60.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Clinical Trials as Topic; Drug Approval; France; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Survival Rate; Treatment Outcome | 2000 |
Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Rate | 2000 |
Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?
Topics: Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosomes, Human, Pair 7; Cytarabine; Female; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Isochromosomes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Remission Induction; Thioguanine | 2001 |
[Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2001 |
Topoisomerase II inhibitor induced leukemia in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Homosexuality, Male; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, AIDS-Related; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Neoplasm Metastasis; Neoplasms, Second Primary; Topoisomerase II Inhibitors | 2001 |
Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Homologous; Vidarabine | 2001 |
[CD7(+) acute myeloid leukemia (M0) associated with a mediastinal bulky mass lesion].
Topics: Adult; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Neoplasms, Multiple Primary; Remission Induction | 2001 |
And the sun keeps shining.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Etoposide; Female; Hair Follicle; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2001 |
An adjustment for a post-randomization variable in the comparison of two treatments for survival.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Likelihood Functions; Models, Biological; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2001 |
Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome | 2001 |
A case of zygomycosis and invasive candidiasis involving the epiglottis and tongue in an immunocompromised patient.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Candida; Candidiasis; Cytarabine; Epiglottis; Fungi; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Neutropenia; Tongue; Tongue Diseases; Zygomycosis | 2002 |
Idarubicin cardiotoxicity in acute myeloid leukaemia.
Topics: Adult; Aged; Heart Diseases; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged | 1992 |
Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Colorimetry; Doxorubicin; Drug Resistance; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Verapamil; Vincristine | 1992 |
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Topics: Cell Division; Daunorubicin; Drug Resistance; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured; Verapamil | 1992 |
[Idarubicin--new aspects of the therapy of acute leukemias. Satellite symposium of the International Symposium on Acute Leukemias. Münster, 24 February 1991].
Topics: Idarubicin; Leukemia, Myeloid, Acute | 1991 |
Idarubicin.
Topics: Adult; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged | 1991 |
Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.
Topics: Adolescent; Adult; Aged; Cost-Benefit Analysis; Costs and Cost Analysis; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Models, Theoretical; Prospective Studies; Remission Induction; Retrospective Studies | 1991 |
Granulocyte-macrophage colony-stimulating factor in acute non-lymphocytic leukemia before and after chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Time Factors | 1991 |
Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
Topics: Adult; Antineoplastic Agents; Cell Division; Daunorubicin; DNA Damage; DNA, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local | 1990 |
Oral idarubicin in elderly acute leukemia and refractory anemia with excess of blasts.
Topics: Administration, Oral; Anemia, Refractory, with Excess of Blasts; Drug Evaluation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute | 1990 |
[Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1990 |
Oral idarubicin in elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged | 1990 |
Alpha-2 antiplasmin in acute nonlymphoblastic leukemia.
Topics: alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Cytarabine; Disseminated Intravascular Coagulation; Fibrinolysis; Humans; Idarubicin; Leukemia, Myeloid, Acute; Plasminogen; Prognosis; Remission Induction | 1989 |
Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1989 |
Idarubicin in combination with etoposide and cytarabine in adult acute non-lymphoblastic leukaemia (ANLL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 1989 |
Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent.
Topics: Administration, Oral; Aged; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male | 1989 |
Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction | 1989 |
A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin.
Topics: Adult; Antineoplastic Agents; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Tumor Stem Cell Assay | 1986 |
4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male | 1987 |
Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Blast Crisis; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 1987 |
Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Topics: Antibiotics, Antineoplastic; Biotransformation; Daunorubicin; Humans; Idarubicin; Injections, Intravenous; Kinetics; Leukemia, Myeloid, Acute | 1987 |
Idarubicin in refractory acute leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Parenteral; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Preliminary results in secondary acute non-lymphocytic leukemia (ANLL) treated with Idarubicin.
Topics: Adult; Aged; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local | 1985 |